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Abstract 
Background 
Acute myeloid leukaemia (AML) is an acute form of cancer that does not affect many 
individuals per year, but has a high death rate. The disease is characterized by an abnormal 
growth in the white blood cells in the bone marrow, which causes anaemia and infections. 
The incidence of AML is around 173 cases each year. Because of the disease’s acute and 
deadly form, patients spend several months at the hospital receiving heavy chemotherapy. 
About one-third of the patients receive transplantation, spending from days up to months at 
the intensive care unit. Improving treatments strategies involves understanding the clinical 
pathway and identifying the associated costs.  
 
Aim 
The aim of this study was to investigate the life expectancy and costs associated with treating 
AML in order to provide a representation of the Norwegian treatment regime. Additionally, 
we wanted to compare our results with a similar study from the UK.  
 
Methods 
A combination of decision tree and Markov models was developed to conduct the study. The 
model is probabilistic with the use of Weibull regressions. By means of individual level data 
from OUS Rikshospitalet we were able to derive time-dependent transition probabilities. The 
outcome is life expectancy and costs per individual in a five-year perspective. Costs were 
considered from a health care provider perspective.  
 
Results 
The result of this study shows a total cost and life expectancy of NOK 1 401 521 and 37.61 
months, per patient. The result indicates a higher life expectancy and costs for young 
compared to elderly patients, depending on inclusion of induction treatment.   
 
Conclusion 
AML life expectancy and costs vary according to clinical pathways and patient characteristic. 
When comparing our results with the UK, Norway appears to have a greater life expectancy 
at a higher cost.    
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1 Introduction  
 
About one third will get cancer (28.8 per cent if female and 35.9 per cent if male) at some 
point in life (Kreftregisteret, 2015b). This might be one of the leading factors of why we tend 
to focus research on this disease and its different forms. One is more likely to get cancer 
types such as breast cancer (if female) or prostate cancer (if male), but common for these 
cancer types is a high five-year relative survival. Acute myeloid leukaemia (AML) on the 
other hand is not frequent, but it is more difficult to treat, and the survival is poorer. Due to 
new and resource demanding treatment methods, the economic burden of cancer (and AML) 
are expected to increase in the future. Therefore, the evaluation of cancer treatment methods 
and monitoring of clinical courses is important (Joranger et al., 2015). This is one of the main 
reasons why it is interesting to look at survival and the cost for this patient group.  
 
There is approximately 173 new cases of AML in Norway per year (Kreftregisteret, 2015a), 
and most patients receive treatment in specialist hospitals. OUS Rikshospitalet (OUS) treats 
around 40 new cases per year. This patient group is costly, especially since almost one third 
receives transplantation which has an estimated cost of roughly NOK 1 million per patient (in 
2001) (Mishra, Vaaler, & Brinch, 2002). In addition, almost all of the patients receive 
chemotherapy, other medicaments and numerous amounts of blood transfusions, which 
together are great cost drivers.  
 
This aim of this study is to investigate the costs and life expectancy of AML patients, in order 
to provide a picture of the Norwegian treatment regime. The foundation of the thesis is a 
similar study by Wang et al. (2014) where the cost and life expectancy in the United 
Kingdom (UK) was calculated. A second intention behind this thesis is to compare our results 
to Wang et al. (2014), and examine whether there are any differences in the amount of people 
treated and the survival of these. This is interesting to do especially since the UK have a 
relatively similar health care system to Norway (social welfare). One can learn from each 
other and additionally this gives a form of validation of the study (cross-validation). Analysis 
of the treatment strategies may be used in economic evaluation and further research. 
 
In order to provide a picture of the cost and life expectancy of AML patients we aim at 
answering the following questions: 
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 What is the five-year survival for AML patients and what is the cost for these 
patients? 
 Do younger patients have higher life expectancy and incur more costs than elderly 
patients? 
 How does our findings compare to the results from the UK? 
 
The topic opened for the possibility to use and develop more theoretical knowledge in the 
fields of economic evaluation, clinical pathways and modelling.  
 
The material is based on individual data from OUS, which is a great contribution when 
modelling a disease, as it contains specific patient data. As far as we know, an identical study 
of AML treatment has not been conducted previously in Norway. In collaboration with 
Medical Doctor (MD) Fløisand at the Haematology ward we have identified the treatment 
course and the associated costs. The Cancer registry has provided register data on the number 
of cases in Norway, which may be used as a source of external validation.  
 
The theoretical framework is modelling and survival analysis, as well as cost analysis. The 
method behind the thesis is quantitative.  
 
Including the introduction, the thesis is divided into nine chapters. The second chapter 
provides information about the background of the disease and treatment strategies. The third 
chapter is about modelling clinical pathways and applicable theories, which is data types, 
disease analytic modelling, survival analysis, cost perspectives and uncertainty. The fourth 
chapter provides the method behind the model including our model, transitions in the model, 
life expectancy and costs. The fifth chapter explains different validation methods appropriate 
for the thesis. The sixth chapter describes the material and involves the data set, estimations 
and cost data. The seventh chapter provides results of the probabilistic sensitivity analysis, 
the comparison between Norway and the UK and validation of the study. The eight chapter 
contains the main findings, general discussion, strengths and weaknesses as well as future 
research. The ninth and final chapter presents the conclusion of the thesis.  
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1.1 Co-writing the thesis 
The thesis has been written in cooperation of two students and we were part of both the 
writing of the theory, methods, analysis and conclusion. The carrying-out of the project was 
done together. Beate Bjørnstad was mainly responsible for the analysis in Stata and Alette 
Glasø Skifjeld prepared the data for analysis. 
 
Both of us have helped out each other, meaning that none of the parts was done completely 
individually. There have been discussions on every topic throughout the process and both 
have been involved in decision-making regarding what to include and how to conduct the 
analysis. 
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2 Background 
 
Leukaemia is characterized by a growth of abnormal leukocytes (white blood cells) in the 
bone marrow. The disease may develop when an abnormal blood cell, which has the ability to 
self-renewal and growth advantage compared to normal cells, creates a leukemic clone. The 
leukemic clone may establish itself if a patient has congenital or acquired failure in the 
immunological monitoring. This clone does not necessarily grow more exponentially than 
normal cells. However, it will have a greater tendency to continue dividing itself and a less 
tendency to differentiate and perish. A leukemic clone will gradually differentiate and grow 
to the point where it has displaced other cells in the bone marrow, and the disruption further 
spreads to the blood system (Gedde-Dahl & Tjønnfjord, 2012). 
 
2.1 Risk factors 
AML is not usually related to life style. However, certain chemical exposure (such as 
smoking) are related to AML (American Cancer Society, 2015). Further, the American 
Cancer Society (2015) states that long-term exposure of high levels of benzene (used in the 
rubber industry, oil refineries, some glues, cleaning products and so on) can be a risk factor. 
The exposure of certain chemotherapies can also be a cause (and this leads to secondary cases 
of AML). Survivors of high-dose radiation exposure, such as atomic bomb blast or nuclear 
reactor accident, have a great increased risk of developing AML. Some blood diseases may 
also increase the risk. Lastly, some genetic syndromes and chromosome problems seems to 
increase the risk of AML. Family history is also a risk factor, in addition to older age and the 
male gender (American Cancer Society, 2015).  
 
2.2 Incidence 
Leukaemia is divided into acute and chronic form, where two sub groups belong to acute 
leukaemia; acute lymphocytic leukaemia (ALL) and acute myeloid leukaemia (AML). These 
must not be mixed up as they are different forms of cancer and have different survival and 
treatment regimes. Among the adult patients who get the acute form of leukaemia, 80 per 
cent will get AML while 20 per cent will get ALL (Gedde-Dahl & Tjønnfjord, 2012). 
Another significant factor regarding the disease is whether it is a primary or secondary case 
(Fløisand, 2015). The secondary type is a reaction of other forms of cancer and therapies. 
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This second type is more difficult to treat, as it tends to be more aggressive. Patients suffering 
from primary case of AML (meaning that that the cancer occurred unrelated to other 
diseases) are more likely to respond to treatment (Fløisand, 2015). 
 
The graph (Figure 1) illustrates the cases of AML “Akutt myeloisk leukemi” and ALL “Akutt 
lymfatisk leukemic”, in addition to the two different forms of chronic leukaemia. The X-axis 
represents age, while the Y-axis is the number of cases. The graph is collected from the Store 
medisinkse leksikon (2015). 
 
 
Figure 1 - Leukaemia cases in relation to age (incidence) 
 
Incidence is defined as the proportion of people who develop a disease (or event) during a 
specific period of time (Hunink et al., 2001). By dividing the number of new cases on the 
number in the population one gets a measure of the incidence.  
 
AML occurs at all ages but is most common in adults. The incidence has an exponential 
increase in individuals aged over 40 years (Pallister & Watson, 2011). This is also illustrated 
in Figure 2. 15 per cent of the children who suffer from leukaemia experience AML. The 
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disease is similar to the disease in adults; however, it can be difficult to treat 
(Kreftforeningen, 2015). 
 
Table 1 - New cases (incidence) per year (average) 
 
 
Nearly one third of the adults diagnosed with leukaemia has AML, and there are about 18 
300 new cases of AML every year in Europe (Pallister & Watson, 2011). There are 
approximately 2600 new cases of AML in UK (NHS, 2014) and 150 new cases in Norway 
(Dahl, 2009). In England and Wales the incidence of AML has risen by 70 per cent since 
1971 in both genders. The increase can be subject to new and improved techniques for 
diagnosing the disease (Dahl, 2009).  
 
The graph on the following page (Figure 2) illustrates the number of new cases in Norway 
from year 2000 to 2013. The average is calculated on data from these years, and might vary if 
more years were included. According to Dahl (2009) the average new cases in Norway is 
150, whereas the average from year 2000 to 2013 is 173 (Kreftregisteret, 2015a). 
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Figure 2 - New cases in Norway (Kreftregisteret, 2015a) 
 
2.3 Diagnostics and symptoms 
The disease typically presents itself with a short history of illness (Pallister & Watson, 2011), 
were the symptoms are fatigue, infections, bruising and haemorrhages, because there are no 
other blood cells to control the leukemic development (Blodkreftforeningen, 2015). 
 
The Figure 3, on the following page, from Cleveland Clinic (2015) illustrates AML though 
(A) bone marrow aspirate and (B) bone marrow biopsy. 
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Figure 3 - Immature myeloblastic cells (microscopic) (Cleveland Clinic, 2015) 
 
AML is a diagnosis outcome if the patient has anaemia with low haemoglobin, low number 
of blood palates and too high number of white blood cells (Blodkreftforeningen, 2015). To 
examine whether one suffers from leukaemia one has to take blood samples as well as a bone 
marrow sample. The examination of the blood sample can indicate whether the patient has 
the disease. However, it is necessary with a test of the bone marrow in order to be certain of 
the diagnosis (Kreftforeningen, 2015). Nonetheless, if it is possible to see the immature 
myloblastic cells under a microscope, the diagnosis is almost certain to be AML 
(Blodkreftforeningen, 2015). These tests are also used when undergoing treatment in order to 
control the effect of the treatment (Kreftforeningen, 2015).   
 
2.4  Treatment 
2.4.1 Chemotherapy and remission 
The treatment is based on substantial dosages of chemotherapy and in some cases it is 
necessary with transplantation of hematopoietic stem cells from bone marrow or peripheral 
blood. The different treatments given are based on the patient’s current condition. The 
therapies used at the Haematology ward at OUS Rikshospitalet are either a combination of 
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Cytarabine and Daunorubicin (Ara-C+Dauno) or Cytarabine and Idarubicin (Ara-C+Ida). 
These two treatments are almost identical. Some patients who have a heart condition will get 
other chemotherapies because Idarubicin and Daunorubicin are toxic for the heart (Fløisand, 
2015). 
 
The treatment of AML is considered potentially curative when the patient is expected to 
tolerate heavy chemotherapy. The treatment consists of an induction treatment followed by 
consolidation therapy. Stem cell transplantation is a treatment option to increase the chances 
of long-term survival after the patient has achieved remission (Blodkreftforeningen, 2015). 
 
New methods are continuously being developed, and it becomes easier to treat the specific 
patients according to their status and molecular genetic testing. 
 
The most important prognostic single factor for survival is whether the patients acquire 
complete hematologic remission (CHR). About 80 per cent of patients younger than 60 years 
reach remission with today’s powerful cytostatic (Fløisand, 2015). The younger the patient is, 
the easier it is to achieve CHR. 40-50 per cent among the patients reaching remission will be 
alive after three years. The cytostatic treatment gives the ability to prolong a patient’s life 
equal to the time the patient lives in CHR (Evensen & Stavem, 2008). For more than thirty 
years Cytarabine has been a part of almost all chemotherapy treatments in order to induce 
remission of AML (Dahl, 2009).  
 
Nearly half of the patients selected by age and prognosis that enter a heavy treatment 
programme, are expected to have better survival, and in best case become disease free (Dahl, 
2009). 
 
After treatment, all patients who are achieving CHR will receive follow-ups in different 
intervals. The patients have follow-ups regularly in the first couple of months, and decreasing 
frequency over time. The follow-ups consist of a test to see if there are any abnormal cells in 
development (Fløisand, 2015).  
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2.4.2 Relapse after treatment 
The possibility of obtaining new remission with the same treatment regime after a relapse is 
estimated to be 30-50 per cent; with increasing results the longer the time lapsed between the 
start-up of new treatment and the end of first treatment. Today’s recommendation is to try a 
new initial treatment conditioned on being over 12 months after the end of the first treatment 
regime. However, patients who experience relapse within the first year of treatment will 
rarely achieve a second remission with the initial treatment, and the prognosis is poor. If new 
remission is achieved, transplantation is often considered to secure remission (Kreftlex, 
2015). 
 
2.4.3 Side effects of treatment 
Both the use of high dosage cytostatic and stem cell transplantation induces great risk of 
unwanted side effects both acutely and in the long term. By unwanted effects of treatment 
one is referring to side effects of the disease or treatment that lasts for more than one year 
after the final treatment, or future health problems that probably is due to the disease or 
treatment (Kåresen, Wist, & Reppe, 2012). 
 
The side effects of AML treatment are severe and may be fatal. The patient needs therefore to 
stay in hospital for several months under the intensive period of the treatment. Complications 
due to treatment can be severe and will require medications and blood transfusions. 
Infections and organ failure are often seen in patients with AML. Some patients, especially 
elderly patients, will die of sepsis (blood poisoning) or other complications during the first 
months, because of the extensive chemotherapy. Medications to supress bacteria and fungal 
infections given in combination with blood palates concentrates, intend to secure proper 
treatment (Kreftlex, 2015).  
 
Cytostatic chemotherapy has severe side effects, since it is very difficult to tell the difference 
between normal and malign tissue. Additionally, the optimal dosage and individual 
customisation is difficult because of the pharmacokinetic variability. Some types of cytostatic 
drugs have effect on the DNA, and one can even become resistant against the chemotherapies 
used. Curative cytostatic chemotherapy is recognised by rapid treatment, high dosage 
intensity and often more substances combined (Kåresen et al., 2012). 
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Nutritional problems from the induction treatment often occur because of nausea, vomiting, 
sore mucosa, diarrhoea, dry mouth, constipation, and changes in smell and taste senses 
(Kreftlex, 2015). 
Stem cell transplantation is a high-risk treatment, as 5-20 per cent of the patients die due to 
complications following the procedure (Fløisand, 2015). The prognosis is best for patients 
who suffer from chronic leukaemia (Store medisinkse leksikon, 2009).  
 
2.4.4 Palliative treatment 
Palliative care is offered to patients not responding to treatment or is unable to receive 
chemotherapy. Palliative care involves pain relief, psychosocial support and a closure near 
end of life (if possible) (Lo, Quill, & Tulsky, 1999). The patients who have terminal cancer 
experience many painful symptoms such as pain, anorexia, fatigue, constipation, dyspnoea 
and depression (Riechelmann, Krzyzanowska, O’Carroll, & Zimmermann, 2007). This gives 
palliative care a complex magnitude, and underlines the importance of care. The most 
common prescribed medications for palliative cancer treatment is opioids (such as morphine), 
corticosteroids (stress relief) and laxatives (increases bowel movement) (Riechelmann et al., 
2007). Typically, palliative care is offered and administered in local hospitals (Fløisand, 
2015).  
 
2.4.5 New methods 
All forms of cancer treatment are constantly under development, and AML is no exception. 
One of the most recent strategies is to investigate the impact of FLT3 (a tyrosine kinase 
receptor) mutations (Thiede et al., 2002). It is found to have an impact on early stem cell 
survival and myeloid differentiation. According to Thiede et al. (2002) the definitive goal is 
to be able to use this information in order to offer the more intensive treatment option, 
transplantation, to patients at high risk, and avoid offering this treatment to patient’s with a 
better prognosis. AML patients displaying FLT3 aberrations are less clinically responsive. A 
consequence is one would want to avoid unnecessary high-risk treatment due to the possible 
fatale outcomes (Thiede et al., 2002). 
 
2.5 Treatment facilities 
AML treatment in Norway is offered at university hospitals in each of the four Norwegian 
health regions, namely Oslo University Hospital, St. Olavs Hospital (Trondheim University 
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hospital), the University Hospital of North Norway, Haukeland University Hospital and 
Stavanger University Hospital (where the last two hospitals belongs to the same region). 
Additionally, there are some local hospitals that treat AML patients. However, these patients 
are old and only offered low dose chemotherapy and palliative care. Most of these patients 
are secondary AML cases (Fløisand, 2015). 
 
2.6 Literature review 
Oria.no (The University of Oslo Library) and Google Scholar have been used to search for 
relevant literature. Searches were made on the topics; Acute Myeloid Leukaemia, Blood 
cancer, Survival analysis, Economic evaluation, Cost analysis, Decision tree, Markov 
models, Modelling diseases, Validation and Stem Cell Transplantation. The relevant articles 
found for this study is included in the thesis. 
 
Furthermore, several books and articles on cancer treatment and blood diseases, as well as 
literature on economic modelling and cost analysis were found through oria.no, and creates 
the insight and foundation used to comprehend, analyse and model AML.  
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3 Modelling the clinical pathway 
 
A pathway may be defined as the journey a patient follows from a given starting point, 
including diagnostics, treatment strategies and follow-ups, the information and staff 
responsibilities (Mould, Bowers, & Ghattas, 2010). An important motivation for identifying 
clinical pathways is to be able to estimate survival and costs for a specific disease.    
 
There are several ways to model clinical pathways. One method is to use register data (from 
the Cancer Registry, Norwegian Patient Registry or other registries), while another is to use 
individual data, which can be found in cohorts from randomized control trials or 
observational studies. Registers may contain general patient data or for instance cause of 
death, whereas cohorts consist of specific data. Regardless of the method chosen, inclusion of 
both clinical outcomes and costs is possible.  
 
This chapter includes the foundation needed in order to model clinical pathways, which 
comprehend register data and cohorts, decision analytic modelling (decision trees, Markov 
models and discrete event simulation), survival analysis and associated concepts, costs and 
uncertainty.    
 
3.1 Register data and cohorts 
The use of register data is widely recognised, but the method has both strengths and 
limitations. It is different from cohort studies in many ways. Firstly, register data is data from 
an entire population that is pre-collected and exists, and it may model both life expectancy 
and costs. An advantage with this type of data set is that confounders might be adjusted for 
the whole population. Register data could be used to model both costs and survival due to the 
detailed level of information, all though the data is not necessary gathered for scientific 
purposes. Register data has the advantage that it can be collected from different sources, 
which makes it heterogeneous. In essence, it is a way to refer to data that is of an unknown 
format and/or content. This may be an advantage in terms of selection bias and the possibility 
of studying rare exposure and outcome measures (Thygesen & Ersboll, 2014). A weakness of 
register data collected from many sources is that the researchers lack control over the data, 
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which it might be subject to different coding between institutions (Thygesen & Ersboll, 
2014).  
 
Potentially missing data is challenging to adjust for. Furthermore, since the data is collected 
on general purposes it may be difficult to make it accurate enough for specific research 
topics. Even though the use of register data is intensive, there are no methodological 
literature developed for this (Thygesen & Ersboll, 2014).  
 
In cohort studies the researchers collects all the specifics needed, such as patient history, all 
though these data sets might be smaller. In registerer data the large sample size can give great 
statistical power, but the size may also make register data prone to confounding. The 
information needed to detect this can be hidden by the fact that one are looking at variables at 
a point in time where the confounding variables were unimportant in regards to the question 
at hand (Thygesen & Ersboll, 2014).  
 
Cohort studies monitor a group that is well defined over time in order to track the transitions 
going from non-cases to cases (Stata Press, 2007). This type of study can be both 
retrospective and prospective. If prospective, the analysis of the study is done alongside the 
intervention. A retrospective viewpoint will then be performed after the intervention is 
completed. A cohort study is relevant when assessing effects of harmful exposures. It can 
also be used to generalize a broader population (Sorlie & Wei, 2011). Furthermore, Sorlie 
and Wei (2011) claims that cohort studies can gather detailed data which reflects current 
clinical practices.  
 
One may model register data or cohorts, but we will focus on modelling by the use of 
individual data. Decision analytic models are normally analysed with the use of cohort 
studies (Drummond, Sculpher, Torrance, O'Brien, & Stoddart, 2005).  
 
3.2 Decision analytic modelling 
A model is a simplified representation of reality, which may be a great communication tool. 
It allows the complexity of a system to be reduced to its essential elements (Caro, Briggs, 
Siebert, & Kuntz, 2012). This implies that a model may present valuable information to 
inform decision makers on questions about medical decisions and how to allocate resources. 
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The appropriate way of building a model is to start by understanding the problem that is 
represented. It is important to understand the health care process or decision that is to be 
made, and conceptualize the problem at hand. The model should represent the components of 
the problem by using a particular analytic method (Roberts et al., 2012). This is possible 
through a decision tree and/or a Markov model. A model gives flexibility and can easily be 
modified if changes are needed, as it is future oriented and could be adapted in many ways  
(Briggs, Claxton, & Sculpher, 2006).  
 
Figure 4 illustrates the components of conceptualizing a model. 
 
 
Figure 4 - Conceptualizing a model (Roberts et al., 2012) 
 
A decision tree is used to estimate the proportion of patients from the cohort who ends up in 
different states (Briggs et al., 2006). Further, the objective of the Markov models is to 
estimate the survival and cost for the cohort depending on how the patients move between 
states (Briggs et al., 2006). This means that in the model the movement between states are 
ignored and all individuals in one state is considered homogenous (Briggs et al., 2006). The 
length of a cycle in a Markov model is defined by the modeller, and can be adjusted to 
correspond to different diseases.  
 
3.2.1 Decision trees 
Decision trees has gained increased popularity in economic evaluation (Drummond et al., 
2005). A decision tree has the initial decision on the left side and flows to the right with 
chance nodes depicted in the tree. The outcomes are given of previous probabilities in the 
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tree (Drummond et al., 2005). The transition probabilities and the different cost for each 
branch can be multiplied and hence be used in evaluation. When building a decision tree one 
have to investigate whether the events occurs more than once and whether the probabilities 
are constant over time (Drummond et al., 2005). A decision tree is useful in order to provide 
a visual overview of the alternatives. Besides, it is used to calculate the probability of ending 
up in the different end points, and this probability is referred to as expected values. The 
pathways in the decision tree are mutually exclusive sequences of events (Briggs et al., 
2006). Accounting for time is not possible with decision trees. This may lead to difficulties 
when implementing models that are time dependent and models that are observing longer 
time periods. A decision tree that contains many branches can become complex. Hence, it 
may be difficult to model complicated long-term diseases, especially chronic diseases, since 
decision trees does not take adverse events into consideration, as one can only move in one 
direction in the three (Drummond et al., 2005).  
 
3.2.2 Markov models 
Markov models are a form of a recurring decision tree. It is possible to combine Markov 
models and decision trees in certain evaluations (Briggs et al., 2006). Markov models are 
based on a series of “states” that a patient can move to at a particular point in time. The cost 
for each cycle can be calculated and incorporated in the model. The probability of moving to 
another state is independent of earlier transitions (Drummond et al., 2005). State 
independency may be difficult to come around when you have previous states that might 
determine the probability of future outcome, and the model can become too simplified. To 
avoid this oversimplification of the model it is possible to add additional states to the model 
that may take this into consideration (Drummond et al., 2005).   
 
The Markov model is entirely defined by the probability distribution between the states and 
the individual probabilities (Sonnenberg & Beck, 1993). The probability can change over 
time as the patient gets older or as the risk of disease is transformed. In Markov models one 
can have absorbing states, defined by the fact that a patient cannot leave that state. In 
modelling diseases, death is an example of an absorbing health state since it is only possible 
to enter, and not leave, this state (Sonnenberg & Beck, 1993). Muenning (2008) argues that 
when modelling cancer patients, the use of Markov models can incorporate the changes in 
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health states over time such as patient recovery or relapse. Further, he says that there is a risk 
that these patients can remain sick over a longer time period.  
 
Figure 5 illustrates how a cohort is transitioning between states, from the initial state to the 
final absorbing state (Sonnenberg & Beck, 1993). 
 
 
Figure 5 - Transitions in a Markov model (Sonnenberg & Beck, 1993) 
 
In a Markov model one assumes there is no memory of where an individual was before it 
moved to a particular state. This is called “The Markov Assumption” (Briggs et al., 2006). 
328
FIGURE 7. Markov cohort simulation. PanelA (top)  shows the initial
distribution with all patients in the WELL state. Panel B (middle)
shows the distribution partway through the simulation. Panel C
(bottom) shows the final distribution, with the entire cohort in the
DEAD state.
MARKOV COHORT SIMULATION
The Markov cohort simulation is the most intuitive
representation of a Markov process. The difference
between a cohort simulation and the matrix formu-
lation may be thought of as analogous to the difference
between determining the area under a curve by divid-
ing it into blocks and summing their areas versus cal-
culating the area by solving the integral of the function
describing the curve. The simulation considers a hy-
pothetical cohort of patients beginning the process
with some distribution among the starting states. Con-
sider again the prognosis of a patient who has a pros-
thetic heart valve, represented by the Markov-state dia-
gram in figure 3. Figure 7A illustrates the cohort at the
beginning of the simulation. In this example, all pa-
tients are in the WELL state. However, it is not necessary
to have all patients in the same state at the beginning
of the simulation. For example, if the strategy repre-
sents surgery, a fraction of the cohort may begin the
simulation in the DEAD state as a result of operative
mortality.
The simulation is &dquo;run&dquo; as follows. For each cycle,
the fraction of the cohort initially in each state is par-
titioned among all states according to the transition
probabilities specified by the P matrix. This results in
a new distribution of the cohort among the various
states for the subsequent cycle. The utility accrued for
the cycle is referred to as the cycle sum and is cal-
culated by the formula:
where n is the number of states, fs is the fraction of
the cohort in state s, and U, is the incremental utility
of state s. The cycle sum is added to a running total
that is referred to as the cumulative utility. Figure 7B
shows the distribution of the cohort after a few cycles.
Fifty percent of the cohort remains in the WELL state.
Thirty percent of the cohort is in the SICK state and
20% in the DEAD state. The simulation is run for enough
cycles so that the entire cohort is in the DEAD state
(fig. 7C).
The cohort simulation can be represented in tabular
form, as shown in table 2. This method may be im-
plemented easily using a microcomputer spreadsheet
program. The first row of the table represents the start-
ing distribution. A hypothetical cohort of 10,000 pa-
tients begins in the WELL state. The second row shows
the distribution at the end of the first cycle. In ac-
cordance with the transition probabilities specified in
the P-matrix (table 1), 2,000 patients (20% of the original
cohort) have moved to the DISABLED state and another
2,000 patients to the DEAD state. This leaves 6,000 (60%)
remaining in the WELL state. This process is repeated
in subsequent cycles. The fifth column in table 2 shows
the calculation of the cycle sum, which is the sum of
the number of cohort members in each state multi-
plied by the incremental utility for that state. For ex-
ample, because the incremental utility of the DISABLED
state is 0.7, the cycle sum during cycle 1 is equal to
(6,000 X 1) + (2,000 X 0.7) = 7,400. The DEAD state
does not contribute to the cycle sum because its in-
Table 2 . Markov Cohort Simulation
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The Markov assumption has three assumptions. The first assumption is population 
homogeneity, which means that all individuals in the study will have the same transition 
rates. The second assumption is called “First-order Markov”, meaning that regardless of past 
history, individuals in the model have the same transition probability. The last assumption is 
that transition rates remains constant over time (Shorrocks, 1976). Increasing the number of 
states and decreasing the cycle length may account for the Markov assumption. When 
creating a Markov model, adjusting the number of cycles is possible to fit the development of 
the disease. A cycle length can vary between everything from days to years (Muennig, 2007). 
 
In order to include time-dependency in the model, different transition probabilities are 
assigned to the different cycles. This means the transition probability will vary as the cohort 
ages (Briggs et al., 2006). Time-dependency means that the time spent in a particular cycle is 
important for the transition from that state. In cancer treatment, a patient in remission may 
have a higher probability of remaining in remission over time; hence the transition 
probability out of that state may decrease over time. This concept is known as tunnel states 
(Briggs et al., 2006). 
 
Half-cycle correction is integrated in Markov models in order to adjust for the fact that 
individuals can experience the event at different times in each cycle (within the individual 
cycle). A half-cycle correction may be conducted in order to smoothen out the area under the 
curve that reflects the expected survival. An uncorrected Markov model can either lead to 
over- or underestimation. Under-estimation means that one are counting the cohorts 
membership at the end of each cycle, while over-estimation means that one are counting the 
membership at the beginning of each cycle. A half-cycle correction will therefore count the 
cohort at the middle of each cycle (Sonnenberg & Beck, 1993). 
 
3.2.3 Discrete-event simulation 
Discrete-event simulation (DES) is an alternative model to the Markov model. The difference 
is that DES is designed to investigate how long an individual will stay in a state, rather than 
how this individual will move to another state (Briggs et al., 2006). In a DES model, 
individuals experience an event at any discrete point in time after the previous event. In 
contrast to the analysis of a Markov model, the analysis of a DES model is generated by the 
occurrence of an event, where the model explores at what and when the next event for an 
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individual occur (Karnon, 2003). Contradictory to Markov models and decision trees, where 
these models assume independence between individuals, DES will account for interactions 
between individuals (Barton, Bryan, & Robinson, 2004). Both Markov models and DES 
models are a way of simulation, where DES allows for more complicated models. Despite the 
flexibility of a DES model, it is more comprehensive to perform because of the requirement 
of more specific model characteristics (Karnon, 2003). 
 
Disease analytic models are possible to use when analysing survival. However, it is important 
to choose one method that corresponds well with the data set.    
 
3.3 Survival analysis 
Survival analysis attempts to answer how many individuals in a population will survival past 
a certain time. This is useful when modelling diseases and investigating the time perspective 
of a disease course.  
 
Today, survival analysis is widely used in several aspects of society. It is used by scientists to 
analyse time until onset of disease, time until stock market crash, time until failure of 
equipment, time until an earthquake and so on. In the field of medicine it is commonly used 
to analyse disease, recovery, relapse and death (Singh & Mukhopadhyay, 2011). Events such 
as these are often referred to as failures (Cleves, Gould, Gutierrez, & Marchenko, 2008). 
Examples of failure are time to a heart attack for a specific patient group, time to remission 
for a particular cancer patient group, and time to death from a heart transplant. This makes 
survival analysis a useful tool in clinical research to provide valuable information about an 
intervention (Singh & Mukhopadhyay, 2011).   
 
Survival analysis is typically used when we have some sort of longitudinal study, e.g. a trial 
or cohort study, which records the time to event for each patient. This can be analysed 
through the relationship between a transition probability and time, which may be explicitly 
estimated from patient-level data (Briggs et al., 2006).  
 
The understanding between rates and probabilities is particularly important because survival 
models employ hazard rates, while Markov models employ probabilities (Briggs et al., 2006).   
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3.3.1 Spell data 
Spell data is survival data representing a fixed period that contains a onset time, failure and 
censoring time, as well as an end time in addition to other measurements taken during that 
specific period (Stata Press, 2007). The concept of censoring will be discussed in the next 
section (3.3.3 Censoring). 
 
In these types of data set one has calendar dates for all events. In order to transform the 
calendar dates to duration (time in remission, time in relapse, time in transplantation etcetera) 
one has to start with the first calendar date (January) and set this to zero. February will be 
one, March three, and so on. When all dates are transformed into duration, it is possible to 
analyse time to failure, which is referred to as “time-variables”.  
 
3.3.2 Censoring 
The key feature of survival analysis is the handling of censoring that often occurs in follow-
up studies. When an individual is censored it means that it is not observed for the whole 
analysis period (Cleves et al., 2008). This means that if an individual was diagnosed in 2011, 
within a five-year perspective, and there are no observations on failure, such as 
transplantation, relapse or death, it should be censored because we do not have enough 
observations on this individual. In essence, when an individual enters late in the chosen time-
span, and it is impossible to observe any events, the individual must be censored. There are 
several types of censoring whereas right censoring is more common. Right censoring implies 
that the failure events has not yet occurred by the end of the chosen perspective, or some 
might have been lost to follow-up (Cleves et al., 2008).  
 
In Figure 6, the concept of right censoring is visualised. The time period is five years, from 
2000 to 2004. Five individuals enter the observational period at different times within a time 
period of five years. Individual 1 enters at time zero and has an event at year five. This means 
that this individual has an observed event during the observational period. Similarly, 
individual 3 has an event between 2001 and 2002, and is recorded as a failure. Individual 2 
enter at time zero and have an observed event past year 2004, which is beyond the time 
period. Event though individual 2 has an event; it will be accounted for as survived. 
Individual 4 is censored, due to short observational time, and no events are observed. 
Individual 5 has no observed events though out the time period and is recorded as survived.   
  21 
 
Figure 6 - Right censoring 
 
3.3.3 Important concepts of survival analysis 
To be able to derive transition probabilities in a survival analysis, it is important to know the 
concepts around survival analysis. The probability density function (pdf) for survival data, 
f(t), with an associated cumulative density function, gives the cumulative probability of 
failure up to time t (Briggs et al., 2006): 
 
 𝐹(𝑡) = 𝑃(𝑇 ≤ 𝑡) 
 
[1] 
The survival function can be rewritten as the complement of the pdf-function (Briggs et al., 
2006): 
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𝑆(𝑡) = 𝑃(𝑇 > 𝑡) = 1 − 𝐹(𝑡) [2] 
Equation [2] defines the proportion alive at time t, where P is the probability of surviving for 
a period of time grater than t. From equation [2] we can relate F(t) to S(t) (Briggs et al., 
2006): 
 
 
𝑓(𝑡) =
𝑑𝐹(𝑡)
𝑑𝑡
=
𝑑(1 − 𝑆(𝑡))
𝑑𝑡
= −𝑆′(𝑡) 
 
[3] 
From equation [3] we can derive the hazard function, which is the instantaneous rate of 
failure at time t, conditional on having survived up to time t (Briggs et al., 2006): 
 
 
ℎ(𝑡) =
𝑓(𝑡)
𝑆(𝑡)
 
 
[4] 
The cumulative hazard function is defined as (Briggs et al., 2006): 
 
 
𝐻(𝑡) = ∫
𝑓(𝑢)
𝑆(𝑢)
𝑡
0
𝑑𝑢 
 
[5] 
It is important to note that the probability of failure up to time t, which is given by F(t), is not 
the same as the cumulative hazard up to time t. By using the results of equation [3] and the 
standard rule of calculus, it could be written as the survival function in terms of the 
cumulative hazard (Briggs et al., 2006): 
 
 𝑆(𝑡) = 𝑒𝑥𝑝{−𝐻(𝑡)} 
 
[6] 
Equation [6] is central to deriving transition probabilities for Markov models.  
 
3.3.4 Different regression models 
There are several ways of estimating survival. The Kaplan-Meier estimator is a 
nonparametric estimator of the survival function S(t), which estimates censoring and failures 
in the data set (Cleves et al., 2008). When estimating survival, The Cox proportional model, 
the Weibull model and the Exponential model are all popular methods. The Cox proportional 
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hazard model is a regression method that provides an estimate of the hazard ratio and its 
confidence interval. It is considered “semi parametric” because it does not require a 
specification of the baseline hazard function. The model assumes that the hazard ratio of two 
individuals is time-independent, and it is only valid for time-independent covariates. This 
means that if an individual has twice the risk of death, compared to another individual, the 
risk of death over time remains twice as high (Singh & Mukhopadhyay, 2011).  
 
Parametric regression, such as the Weibull model, is able to handle problems of time-varying 
covariates, delayed entries, gaps and right censoring. Parametric estimation is appropriate 
when you have an idea of how the baseline hazard looks like. The Weibull model allows the 
hazard to grow (or decrease), and it also gives better estimates when the estimated cumulative 
hazard is increasing at an increasing rate (Cleves et al., 2008).  
 
The Exponential model is the simplest model to use because of the assumption of a constant 
baseline hazard (Cleves et al., 2008). Exponential models are useful when solving problems 
involving population changes. When a change in a quantity over a period of time occurs at a 
pace that is proportional to the quantity size, the exponential model is useful in looking at 
growth or degeneration (Newbold, Carlson, & Thorne, 2013). 
 
Strengths and limitations 
Because of the constant baseline hazard in the exponential model, the model lack memory of 
the failure process. In other words, the failure rate is independent of time (Cleves et al., 2008) 
The limitation of the Cox proportional hazard model is that it does not specify how the risk of 
an event will change over time (the hazard function). Hence, it is not useful when looking at 
time-dependency in a Markov model (Briggs et al., 2006). However, in the Cox model the 
magnitude of the time variables does not matter, rather, the purpose of the model is to 
determine who is to be compared to whom (Cleves et al., 2008).  
 
The Weibull model is advantageous when modelling time dependency (Briggs et al., 2006), 
and has the ability to provide reasonably precise failure analysis with extremely small 
samples (Abernethy, 2006). In modelling cancer treatment, it is common to use the Weibull 
model (Nadler & Zurbenko, 2013). Since time plays an important role in Weibull, adding risk 
to the time variables will change the accumulated risk (Cleves et al., 2008).  
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3.3.5 Parametric regression using Weibull 
Formula of the Weibull distribution and the corresponding hazard function and survival 
function are as follows (Briggs et al., 2006): 
 
 𝑓(𝑡) =  𝜆𝑝𝑡𝑝−1𝑒𝑥𝑝{−𝜆𝑡𝑝} [7] 
 
 ℎ(𝑡) =  𝜆𝑝𝑡𝑝−1 [8] 
 
 𝑆(𝑡) =  𝑒𝑥𝑝{−𝜆𝑡𝑝}                    [9] 
 
The shape parameter 𝑝 (Gamma) is the parameter estimated from the data, which determines 
the shape of the hazard function, while the scale parameter 𝜆 (Lambda) gives the scale of the 
distribution. The hazard rate will fall over time when the shape parameter 𝑝 is between 0 and 
1. The distribution of this model is able to provide a variety of monotonically increasing or 
decreasing shapes of the hazard function, and their shape is determined by p. When p = 1, the 
hazard is constant (horizontal line) so the model reduces to the Exponential model (Cleves et 
al., 2008). 
 
Figure 7 illustrates the different shapes the time-dependent hazard rates can yield. This figure 
is drawn based on fig. 3.2 (p.54) in Briggs et al. (2006) 
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Figure 7 - Different shapes of hazard rates 
 
 
3.3.6 Survival analysis in Stata 
We used the statistical program Stata to calculate the transition probabilities, incorporation of 
correlations between parameters, and correlations between estimates, in order to analyse 
survival.  
 
To perform survival analysis in Stata one has to use the stset command. This command 
declares the data to be st data, which informs Stata of the key variables and what role they 
play in the survival analysis (Stata Press, 2007). The purpose of this is to make Stata describe 
when an observation is included and excluded and what defines the start of risk and failure 
(Cleves et al., 2008). The entry and exit time indicate when a subject is first and last under 
observation (Stata Press, 2007). The entry and exit time is recorded in time units. If there are 
only one record per individual, the case of failure or no failure, the data is a single-record 
data. Stata is detecting who is censored when we declare which variable is the time-variable 
and which variable is the failure/no-failure variable (Stata Press, 2007).  
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When the data is stset, Stata creates three new “response” variables corresponding to the data 
set. These new variables are t0, t, d. t0 marks the beginning of the time span, t marks the end 
of the time span and d indicates failure (denoted as 1), censoring and no failure (denoted as 
0). These variables are based on the information in the data set and generate an indicator 
variable (_st) that records whether the observations are relevant to the analysis. This means 
that by executing the command stset we are ensured that the data we are analysing use the 
same response variables. All other st commands, such as regression, that are performed after 
stset work with the variables Stata generated, rather then the original variables in the data set 
(Cleves et al., 2008).  
 
When the data is declared as survival-data, the command streg can be used to look at the 
likelihood estimation for parametric regression survival-time. (Stata Press, 2007). 
Using the command streg, with different options for which model you want to use, fits 
parametric models. In Stata ln_p, p and 1/p are three parameterizations of p. The first 
parameterization represents the metric in which the model is actually fit. When estimating in 
this metric, we are assured of obtaining an estimate of p that is positive, and the estimation of 
p is obtained by transforming ln(p) post estimation. The third parameterization is given so 
that one may compare these results with those of other researchers who commonly choose to 
parameterize the shape in this manner (Cleves et al., 2008) 
 
stcurve can be used after fitting a Weibull model. We use this command to plot the fitted 
survival, hazard and the cumulative hazard functions. stcurve evaluates the fitted model at 
each time in the data, both censored and uncensored, and computes the means of the 
covariates. This means that the resulted curve is the experienced survival of a subject with a 
covariate pattern equal to that of the average covariate pattern in the study (Stata Press, 
2007).  
 
The command matrix list e(b) will give us the coefficients from the regression analysis, while 
matrix list e(V) gives us the covariance matrix. This is used to calculate the hazard functions 
in Excel (Cleves et al., 2008).  
 
See the complete do-file from Stata in Appendix N. 
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3.4 Cost 
According to Drummond et al. (2005), economic evaluation is a comparative tool when 
looking at alternative courses in terms of their costs and consequences.  
  
in economic evaluation it is common to use either the health care provider or the societal 
perspective (Frick, 2009). Undertaking the social perspective would need all costs including 
transport, involvement of family members, sick leave and so on (Drummond et al., 2005). 
From the perspective of the health care provider one only need the cost associated with the 
treatment strategies. Most evaluations has a narrow perspective and the focus is on the 
relevant costs based on the background of the study (Drummond, Weatherly, & Ferguson, 
2008) 
  
Identification, quantification and valuation of costs are an important aspect of economic 
evaluation. Identifying costs means that one has to define the target population in order to 
detect the appropriate resource use. The clinical pathway of the population can be used in 
order to obtain this information of resource use. Quantification of costs relates to the amount 
of resources used by the target population, which may be acquired by specialists (expert 
opinion), registries and guidelines. Valuation refers to the collection of price weights from 
the target population experiences, which is multiplied by the resource use. One way to assess 
price weights is by using administrative data, such as billing records (Glick, 2007).   
 
Cost analysis may be used to compare the cost of relative effectiveness between different 
strategies. As found in an article by Lowson, Drummond, and Bishop (1981), the most cost-
effective methods for the given health care provider might depend on the already existing 
facilities. If one conduct a cost analysis one must decide on how precise the cost estimates 
shall be. At a micro-costing level one are including the cost for the doctors and nurses, as 
well as operating costs, equipment, blood products and pharmaceuticals. At a case-mix level 
one looks at the cost for each hospital patient and takes length of stay into account. A micro-
costing level and a case-mix level are most precise in estimating costs. The detail level of 
each case is determining the level of precision. If one uses the disease-specific per diem or 
average per diem level one only looks at averages. These are the least precise cost estimates 
(Drummond et al., 2005). 
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3.4.1 Net health-care costs 
Based on Weinstein and Stason (1977) the following expression can be used to calculate the 
net health-care costs of a clinical pathway: 
 
 
𝐶 = ∑ 𝑞𝑘𝑐𝑘
ℎ
𝑘=1
 
[10] 
 
C = Total health-care costs 
 
h = Heath care service 
 
k= Health care service k, where k=1,…h 
 
𝑐𝑘 = Includes all direct medical and health-care cost (hospitalization, physician, medication, 
laboratory, counseling and other ancillary services) and all health-care costs associated with 
the adverse side effects of treatment, k. 
 
𝑞𝑘 = Refers to the quantity of resources used in relation to treatment, k. 
 
3.5 Uncertainty 
Uncertainty as a concept is important in evaluation, because uncertainty is usually in all ways 
of modelling and in the input parameters. It is therefore important to understand how to deal 
with uncertainty (Briggs et al., 2006).  
 
According to Briggs et al. (2006) there are four key concepts in understanding uncertainty 
and heterogeneity in decision modelling. These can be divided into variability, parameter 
uncertainty, decision uncertainty and heterogeneity. 
 
Variability refers to the difference between patients, which, for instance, can be differences in 
experienced clinical event, response rate or treatment strategies. According to Briggs et al. 
(2006) this variability cannot be adjusted for through the collection of additional data. This 
will not be discussed further. Parameter uncertainty refers to the precision of the estimation 
of an input parameter, for instance, a probability or a mean cost that is entered into a model. 
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In principle, this uncertainty can be reduced through collecting additional evidence. Decision 
uncertainty refers to the uncertainty when making a decision about your findings. Since 
parameters can be uncertain, one should take precautions when making a decision based on 
your findings. Heterogeneity refers to a form of variability, where patient characteristics may 
differ (Briggs et al., 2006). 
 
By applying a probabilistic or deterministic sensitivity analysis we can deal with parameter 
uncertainty (Briggs et al., 2006). Examples of deterministic sensitivity analysis are one-way 
and multiway sensitivity analysis. In a one-way sensitivity analysis the estimates for each 
parameter are varied on at a time to see how this will change the results, for instance 
expected values. In a multiway sensitivity analysis, the estimate for more than one parameter 
varies within a specific range. In a probabilistic sensitivity analysis (PSA), distributions are 
added to the probability parameters. The uncertainty in the probability parameters would be 
characterized by the distributions. A second stage of PSA is to undertake a Monte Carlo 
simulation. Monte Carlo simulations calculate expected values a multiple number of times, 
were each simulation is drawing from a random draw from each of the input parameter 
distributions. The outcome is a large set of expected costs and effects that reflect the 
combined parameter uncertainty in the model (Drummond et al., 2005) 
 
In a decision tree with two options, a beta distribution will be appropriate for reducing the 
uncertainty because it bounds between zero and one, while a decision tree with three or more 
branches would need a Dirichlet distribution (Drummond et al., 2005). When estimating 
uncertainty in costs a gamma distribution is appropriate, since it is constrained on the interval 
between zero and positive infinity (Briggs et al., 2006). 
 
3.5.1 Cholesky decomposition 
Once regression is estimated, the calculation of the transition probability as a function of the 
patient characteristics is possible. By doing this, we are assured an adjustment for 
uncertainty. The reason for using the Cholesky decomposition is that it is a way of 
controlling for uncertainty in the covariates between estimates, where the covariate is a 
variable that can affect the relationship between an independent and dependent variable. 
Estimating the variance of the linear predictor from the covariance matrix directly is also 
possible. However, it is important to note that this approach is not appropriate for survival 
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models with more than one parameter. When incorporating the Cholesky decomposition we 
ensure that the λ (lambda) and p (gamma) parameters are appropriately correlated on the log 
scale. This will reduce the uncertainty in the estimated transition probabilities (Briggs et al., 
2006).  
 
The Cholesky decomposition is a lower triangular matrix of the variance-covariance matrix 
(where all cells above the leading diagonal are zero). This variance-covariance matrix is 
easily obtained from a standard regression model. One can call the variance-covariance 
matrix V and the Cholesky decomposition matrix T, such that T multiplied by its transpose 
gives the matrix V. In this way, we can regard the matrix T as the square root of matrix V 
(Briggs et al., 2006). Constructing the correlation matrix is important because even though 
some parameters do not have a strong relationship there might be strong relationships within 
the set of parameters, especially between the regression constant and the other parameters 
(Briggs et al., 2006).   
 
From the variance-covariance matrix we can calculate a vector of correlated variables, vector 
x. To start, we generate a vector (z) of independent standard normal variates and apply the 
formula: x = y+Tz, where y is the vector of parameter mean values. If we have two 
correlating variables, the starting point is to write down the general form for a Cholesky 
matrix, T, and multiply this matrix by its transpose to get a 2 × 2 matrix. Further, this matrix 
can be set equal to the variance-covariance matrix (Briggs et al., 2006): 
 
 
(
𝑎 0
𝑏 𝑐
) (
𝑎 𝑏
0 𝑐
) = (𝑎
2 𝑎𝑏
𝑎𝑏 𝑏2 + 𝑐2
) = (
𝑣𝑎𝑟(𝑥1) 𝑐𝑜𝑣(𝑥1, 𝑥2
𝜌𝑠𝑒(𝑥1)𝑠𝑒(𝑥2) 𝑣𝑎𝑟(𝑥2)
) 
 
[11] 
When we have a known variance-covariance matrix it is easy to solve the unknown a, b and c 
components of the Cholesky decomposition matrix for the known variance and covariance 
(Cholesky) (Briggs et al., 2006): 
 
 
(
𝑎 0
𝑏 𝑐
) = (
√𝑣𝑎𝑟(𝑥1) 0
𝑐𝑜𝑣(𝑥1, 𝑥2)
𝑎
√𝑣𝑎𝑟(𝑥2) − 𝑏2
) 
               = (
𝑠𝑒(𝑥1) 0
𝜌 ∙ 𝑠𝑒(𝑥1) √1 − 𝜌2 ∙ 𝑠𝑒(𝑥2)
) 
[12] 
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To generate correlated random variables we need to use the original Cholesky expression; x = 
y+Tz (Briggs et al., 2006):  
 
 (
𝑥1
𝑥2
) = (
𝜇1
𝜇2
) + (
𝑎 0
𝑏 𝑐
) (
𝑧1
𝑧2
) 
 
[13] 
where μ is the expected value, x are the correlated variables, the matrix a, b, c and 0 is the 
Cholesky decomposition matrix and z is the vector of independent standard normal variates. 
Multiplying this equation out gives the adjusted coefficients (Briggs et al., 2006):  
 
 
(
𝑥1
𝑥2
) = (
𝜇1 + 𝑎 ∙ 𝑧1
𝜇2 + 𝑏 ∙ 𝑧1 + 𝑐 ∙ 𝑧2
) 
 
[14] 
Then we can substitute a, b, and c for what we defined previously (Briggs et al., 2006): 
 
 
(
𝑥1
𝑥2
) = (
𝜇1 + 𝑠𝑒(𝑥1) ∙ 𝑧1
𝜇2 + 𝜌 ∙ 𝑠𝑒(𝑥2) ∙ 𝑧1 + √1 − 𝜌2 ∙ 𝑠𝑒(𝑥2) ∙ 𝑧2
) 
 
[15] 
The first random variable will require the mean and standard error. The second random 
variable will require mean and standard error given by the associated parameter’s mean and 
standard error. Through the shared component of variance 𝑧1, the correlation is introduced in 
proportion to the overall correlation (Briggs et al., 2006).  
 
Having executing these steps, we can insert a distribution and a random variable to make the 
transition probabilities probabilistic. This creates vectors of standard normal variates (z). The 
next step is to enter the solutions from the Cholesky decomposition matrix and multiply this 
by the vector of standard normal variates (Tz). Further; we need to add the estimated mean 
values from the regression to Tz. This will create a vector of multivariate normal parameters 
that are correlated according to the estimated covariance matrix, mu + Tz. The mu + Tz 
make up the coefficient in the survival analysis for baseline hazard. The mu is extracted from 
the regression coefficients (Briggs et al., 2006).  
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4 Method 
 
4.1 The model 
 
4.1.1 Overview 
For the AML patients the clinical pathway involves longer periods at the hospital due to 
intensive chemotherapy treatment and a high infection rate. The patients do not necessary 
respond equally and a complete standardisation of the model could be difficult. Almost all 
patients receive an induction treatment. The decision tree and the Markov models in this 
thesis can be looked at as the clinical strategy for this patient group. The reason for 
combining a decision tree and Markov models is because of the clinical picture. The decision 
tree is structured to simulate the short-term survival and costs until response (remission) was 
achieved, while the Markov models are investigating the long-term effects. The time horizon 
is five years, while the cycle length is one month.  
 
In this chapter we will explain the structure of the model, and the details of calculating 
transition probabilities and costs.  
 
Figure 8 is a visual illustration of the movements along the branches of the decision tree 
(induction treatment), and how the patients are moved over in the Markov models. Further, it 
visualizes the movement in and between the Markov models. A complete view of our 
decision tree can be found in Appendix L, and additionally screen-prints of the Markov 
models Transplant, Palliative and A1 (young) are found in Appendix A, B and C. The 
patients move from the tree to the respective Markov models according to their response on 
induction treatment. The decision tree and the Markov models will be presented separately, 
as they represent two different ways of modelling. In our Markov models the cycle length is 
one month because this is the most suitable time interval for AML. 
 
The sections describing the induction treatment and the further transactions (Markov models) 
below are referring to the different labels and text in Figure 8. 
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Figure 8 - Decision tree and Markov models 
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4.1.2 Induction treatment (decision tree) 
The model is based on a decision tree that estimates the probabilities of having response, no 
response, no induction treatment and early death. The beginning of the tree is made out of 
branches and different nodes. In the model the entire group of AML patients start at the same 
point, a starting point that is recognized by a squared box. The squared box indicates that 
there are two alternative options (Briggs et al., 2006). In the model this is where the patients 
are divided into groups according to age. The age groups are 16-59 years and 60 years and 
older. The second point in the tree is also a squared node and this defines those who receive 
induction treatment and those who receives palliative care only. This is similar for both of the 
age groups.  
 
The branch for those who does not receive treatment has no more options, and a box “C” 
illustrates the end point. The box “C” is used to indicate which Markov model the patients 
who did not receive treatment are entering. Among those who receive induction treatment 
there are three new branches and the chance node is circular. This circle is used to indicate 
when there are more than two options, and where the probability of receiving a specific 
treatment is uncertain for the individual patients (Briggs et al., 2006).  
 
For both of the patient groups “Ara-C+D”, “Ara-C+I” and “Other” indicate the three 
branches that follow the circular node. All of these treatments are different forms of 
chemotherapy. Ara-C+D and Ara-C+I are treatment options representing today’s practice, 
and are very alike. The third option “Other” is a less heavy form of chemotherapy which is 
given to patients with for example heart conditions. All of these branches end up in a new 
circular node where the three new branches are “Response”, “No response” and “Early 
death”. These three options are also similar for all of the treatment branches. For the young 
patient group the end point of “Response” is shown as a box “A1” and “No response” is 
shown as “B”. “Response” in the older patient group is shown as a box “A2” and “No 
response” is shown as a box “B”. Response is equal to achieving remission.   
 
The branch “Early death” is a terminal state and ends in the tree. This means that the patient’s 
whom ends up there do not continue over in on of the Markov models. These endpoints are 
the same for both groups.  
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In the case of AML, independent of age group, the patients either ends up in the branches 
“Response” (Markov model A1 young and Markov model A2 elderly), “No response” 
(Markov model B for both age groups), “Did not receive (Markov model C for both age 
groups)” or “Early death”.  
 
4.1.3 Treatment after induction (Markov models) 
To know which patients who enter the Markov models, and where they enter the models, the 
expected values of the decision tree are used. If the patient’s belongs to “A1” or “A2” they 
will enter the Markov model A1/A2 (young/elderly) in the box called “1st remission”. This 
state has several possible transitions, which is indicated by the arrows in the model. The 
arrow that loops the different states indicates that it is possible to remain in the state (tunnel 
state).  
 
From “1st remission” it is possible to move to the states “1st relapse”, “Death” and to a new 
health state, transplant “Markov model D” which is a model capturing patients receiving 
transplantation. From relapse the patients can either stay, move to remission or die. Second 
and third remission has the same structure as first remission, in terms of possible pathways. 
Patient who ends up in “No response”, or “Did not receive induction treatment” from the 
decision tree enters the respective Markov models “B” or “C” (palliative care). In these 
models patients can either remain in the state or die.  
 
The Markov model “D” (transplantation) capture, as already mentioned, the patients who 
receives transplantation. Patients can only receive transplantation if the patients are in 
remission and hence the arrows that point to this model comes from “1st remission”, “2nd 
remission” and “3rd remission”, in Markov models A1/A2. From the state “Transplantation” 
you can either stay, which is the opted alternative, or move to “Relapse or “Death”. The 
patient is not moving to any state called remission, rather it is recovering from the 
transplantation and remains in remission. The state identified as “Remission”, which is 
coloured in grey, is not included in our analysis. This is because we do not have any patients 
who achieve remission after relapse in our data set. However, it is technically possible to 
move to this state. If we had any patients in this state they could either stay in that state or 
move to “Relapse” or “Death”. This means that similar to the A1/A2 model, the patients can 
move from a remission to a relapse and in to a new remission state.  
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Patients cannot move in other directions than the arrows indicate, and they cannot move 
between the different Markov models, except to the model D, transplantation. The Markov 
models are based on monthly cycles and all states are mutually exclusive.  
 
4.2 Transitions in the model 
There are five separate Markov models in this study and there are calculated transition 
probabilities for every possible event and cycle. The probabilities are time-dependent, which 
means that they change for every cycle. 
 
4.2.1 Transitions in tunnels 
Tunnel states in a Markov model enable integration of health experiences from the previous 
cycles (Sato & Zouain, 2010). Incorporating heterogeneity and simultaneously estimating 
survival and cost according to age groups, is possible by using tunnels (Joranger et al., 2015). 
The word “tunnel” indicates that the patients can only move in a pre-determined order (Sato 
& Zouain, 2010).  
 
Based on the structure of Joranger et al. (2014), the transition probabilities are defined as: 
 
 
𝑡𝑝 
𝑓, 𝑠
𝑡, 𝑎
= 𝑡𝑝 
𝑓𝑟𝑜𝑚, 𝑡𝑜
𝑡𝑖𝑚𝑒 𝑖𝑛 𝑡𝑢𝑛𝑛𝑒𝑙 , 𝑎𝑔𝑒
 
 
[16] 
f = the health state from which the patient was moving 
s = the heath state to which the patient was moving 
t = number of months (time) the patient has been in the tunnel 
t = 1, 2…60 
t = 0, the patient had not entered a tunnel, but was in one of the treatment states 
a = the age of the patient leaving a health state 
 
For the purpose of transparency Table 2, 3, 4, and 5 shows a small extraction of Markov 
model A1 (young, first remission), A1 (young, first relapse and second remission), D 
(transplant), and C (palliative care) as performed in Excel. All remission states in all models 
are tunnel states, in addition to the non-curative care in model B and C, meaning they are 
time-dependent. The tunnels states are extracted for 18 months, from cycle zero to cycle 18. 
Cycle 19 to cycle 60 were given a mean transition probability for every tenth cycle. It was 
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assumed that individuals could transition to transplantation in all cycles in all remission 
states. The transition probabilities in all models are calculated by employing Equation [16].  
 
Table 2 - Transitions in Markov model A1 (young) – first remission 
 
 
Cycle 0 in Table 2 picks up the patients who ended up in the branches labelled “A1” (young) 
in the decision tree. In cycle 1 the cell picks up the information from cycle 0 and the amount 
of people who leaves remission during the first cycle. The probability of leaving first 
remission in cycle 0 or any other cycle is calculated by those who stay in remission 
subtracted by the sum of those who leave from remission to relapse, transplantation and 
death. The probability of staying and leaving remission is calculated similarly for all cycles in 
first remission, except that the probabilities take account of the time in first remission, 
meaning they are time-dependent.  
 38 
Table 3 - Transition probabilities in Markov model A1 (young) - relapse 
 
 
Table 3 shows both the first relapse and the beginning of the second remission. In cycle 0 
there are no patients because it is impossible to both enter the model in cycle 0 in first 
remission and at the same time enter relapse. The patients, who enter relapse, enter in cycle 1 
from first remission. In cycle 2 the patients who stay in relapse are added from the previous 
cycle with those who left the first remission, and the patients who leave relapse to death is 
subtracted from the previous cycle. In next column, denoted as 1, the patients enter second 
remission in cycle 2. Patients who enter cycle 2 are those who enter second remission from 
first relapse. In our data set it is calculated as one minus those who stay in relapse. Cycle 3 in 
second remission add those who stay in second remission from previous cycle, and subtract it 
with those who leave second remission to second relapse, transplantation and death in 
previous cycle. The cycles in second remission are tunnel stats that are extracted for 18 
months. 
 
Second relapse is calculated in the same way as first relapse. However, we had to use the 
same transition probabilities as first relapse, because we did not have enough data to calculate 
the estimates. We also had to make simplifications for the transition probabilities in third 
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remission for the same reason as in second relapse. We assumed that the transition 
probabilities for second remission were the same as in third remission. Nevertheless, there are 
not many patients who experience a third remission; therefore the probabilities will have little 
impact on the results.  
 
The last state is death. This adds the probability of dying in each cycle in all states. It is made 
cumulative by adding those who died in previous state.   
 
Model A2 (elderly) is calculated by using the same method as in A1 (young), described 
above. However, those entering model A2 are entering from response in the decision tree, for 
the older patient group. The transition probabilities in this model are adjusted for age by 
using the mean age of the older patients. See Appendix H and Appendix I for precise 
calculations.  
 
Table 4 - Transitions in Markov model D - Transplantation 
 
 
Table 4 shows the model D (transplantation). It displays those in the cohort who enter from 
first, second and third remission in model A1 and A2. In cycle 0 there are no patients due to 
the fact that they do not enter this model until cycle 1. Those who leave second remission 
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from cycle 2 enter model D (transplantation) in cycle 3, while those who leave third 
remission from cycle 3 to transplantation enter in cycle 4.  
 
In cycle 2, patients who stay in transplantation (remission) are added from the previous cycle 
(1) and subtracted with those who leave to relapse and death from transplantation 
(remission). This formula is consequent throughout the model and similar to the other 
models, the transition probabilities are in relation to the respective cycles. If one enters 
relapse in this model you can either stay in this state or die. The state “death” is calculated by 
adding those who dies in transplantation/remission and relapse. Transplantation/remission is 
a tunnel state that is extracted for 18 months.  
 
Table 5 - Transitions in Markov model C – Did not receive induction treatment 
 
 
Table 5 shows those who did not receive any treatment in the decision tree (“no induction 
treatment”). We assumed that the patients enter the Markov model C (“Palliative care”) 
directly. The first cycle is referring to those who enter from the decision tree, both young and 
elderly patients. In this model there are only two options: stay in palliative care or death. 
Therefore, cycle 1 is those who enter the model in previous cycle subtracted by those who 
leave palliative care, meaning death.  
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Model B “No response” has the exact same construction as model C “Palliative” (no 
induction treatment). However, the transition probabilities are different, and the first cycle 
imports the individuals from the “No response” branch in the decision tree. For both model B 
and C the transition probabilities are time-dependent and tunnel states, and extracted for 18 
months. 
 
4.2.2 Time-independent transition probabilities 
For all cohorts that are not sufficiently large, time-dependent transition probabilities are 
difficult to calculate. Instead one may use time-independent transition probabilities. Moving 
from a one-year to a one-month cycle length involves more than dividing the transition 
probability by 12 (Briggs et al., 2006). The formula for calculating an instantaneous event 
rate, if we assume 100 patients are followed up for five years, where 20 of those patients had 
a particular event, will be (Briggs et al., 2006): 
 
 
𝑅𝑎𝑡𝑒 = −
[ln(1 − 0,2)]
5
 
 
[17] 
The one-month probability of the event is (Briggs et al., 2006): 
 
 = 1 − exp (−𝑟𝑎𝑡𝑒 ∗ (1/12)) 
 
[18] 
where the rate is referring to the instantaneous event rate found in Equation [17]. 
 
4.3 Life expectancy 
Calculating life expectancy will illustrate how long an average patient live after the date of 
the AML diagnosis. It is also possible to estimate the life expectancy according to age group 
and for the different Markov models. To calculate this, we added the proportion alive in each 
cycle, across all cycles, and over all models (Briggs et al., 2006). This was done for all 
Markov models, separately. We also looked at the total life expectancy for all models 
(decision tree and Markov models) combined.  
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4.4 Cost 
The respective costs are multiplied by the respective cycle probability for each model. This 
gives us an average cost per patient. Costs are added up in each model and discounted with a 
discount rate of 3.5 per cent. The costs reflect the resource use for the patient group at OUS. 
We have included both fixed costs and variable costs for medications.  
 
Based on Drummond et al. (2005) the discount factor is: 
 
 𝑐/(1 + 𝑟)𝑛 [19] 
 
where n is the year of discount, r is the discount rate and c is the cost we want to discount.  
 
4.4.1 Costs in the decision tree 
When implementing costs in a decision tree one uses a combination of the expected values 
and the calculated cost for each branch. This means that the expected costs are based on the 
sum of the pathway cost multiplied with the pathway probabilities (Briggs et al., 2006). The 
costs that incur in the tree are cost of diagnosis and induction treatment (including length of 
stay and medicaments), and in some cases intensive care. 
  
4.4.2 Costs in the Markov models 
To implement costs in a Markov model one multiplies the monthly or annually cost 
(depending on the cycle length) associated with the different states with the probability of 
being in each state. In other words, one adds the cost of each state weighed by the proportion 
in the state and then adds across cycles (Briggs et al., 2006). If one conducts this in Excel, a 
column can be made in the end of the Markov model where one adds up each of the cycle 
probabilities multiplied with each associated cost across the rows. The overall expected cost 
can be found by adding the expected cost of every cycle (Drummond et al., 2005). In the 
Markov models the costs that are included is chemotherapy, consolidation therapy, 
transplantation, palliative care and follow-up, each according to the model the individuals 
belong to. Patients can also receive treatment at the intensive care unit. 
 
The costs are included at a case-mix costing level which means that we have data on the 
mean quantity of resources and the cost of these (Frick, 2009). The hospital cost are in direct 
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allocation with the Haematology ward and do not include interaction with other wards, with 
exception of the intensive care ward and palliative care treatment. 
 
4.5 Important simplifications of the model 
All models are a simplification of the real picture (Drummond et al., 2005). In order to make 
the model as accurate as possible one must make some decisions on what to include and not 
according to what is appropriate. Table 6 is a summary of the features of the model. 
 
We will discuss the simplifications of this model in the Discussion chapter, but a short 
summarization of what factors is omitted is given below: 
 Only patients from one hospital 
 The patients are divided into two groups which means that it is not completely age 
specific 
 The time frame is five years, which means that patients who has more than two 
relapses falls out of the model 
 The probability from second remission to second relapse and second remission to 
death in model A1(young) and A2 (elderly), and relapse to death in transplant is 
simplified 
 QALY is not included 
 Molecular genetic testing is not included all though it can be used in order to avoid 
unnecessary transplantations 
 The interval for follow-ups is average estimates 
 The amount of patients and costs of those who receives treatment at the intensive 
care ward is based on expert opinion. The estimate is five per cent of the patients 
 The amount of people who achieve remission after relapse in the transplantation 
model is not included 
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Table 6 - Overview of the model features 
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5 Validation 
 
Validation is an important part of doing research. One has to investigate how reliable the 
research actually is. Validity is the power of an instrument to measure what it is supposed to 
predict (Kumar, 2011). The information can be used to support decision makers when 
determining the applicability of the results (Eddy et al., 2012). 
 
Validation cannot be a general specification for all models. Rather, it has to be conducted 
according to particular applications, since models can have different levels of validity for 
different uses. For instance, when examining how an intervention will increase or decrease its 
costs, the need for accuracy is less important. To answer specific questions on how much an 
intervention will cost, accuracy is highly important (Eddy et al., 2012).   
 
5.1  Internal validation 
Internal validation is testing the model (Steyerberg, 2009). The method controls that the 
model has been applied correctly and that the mathematical calculations and the coding is 
correct (Eddy et al., 2012). A way to control the research’s internal validation is by 
explaining the code to others and search for mistakes. Further Eddy et al. (2012) suggests 
sensitivity analysis, trace analysis and extreme value analysis to control for errors.  
 
 
 
 
 
 
 
 
 
 
Figure 9 illustrates both internal and external validation. 
Figure 9 - Internal and external validation (Steyerberg, 2009) 
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5.2 External validation 
External validation simulates events that have occurred (e.g. clinical trials) and examine how 
well the results correspond to real data (Eddy et al., 2012). This type of validation can be 
used to measure several outcomes including disease incidence and progression. The three 
main steps of conducting an external validation is; 1. Identifying the data sources, 2. Do the 
simulation, and 3. Compare the results. This type of validation tests the model’s capacity to 
calculate actual results, and should be used in parts of the study that is covered by data 
sources. It can be difficult to assess external validation for costs and resource use, as cost 
units can vary greatly across settings (Eddy et al., 2012). 
 
5.3  Face validation 
A criterion for face validation is that people who have expertise in the field judge the model. 
Further, the researchers must provide supporting evidence and information about the model 
(Eddy et al., 2012). The role of the expert is to ensure that that the results make sense 
(Weinstein et al., 2003). A strength of face validation is that it helps to ensure that the 
researchers have followed the current medical practises and the best available support 
material (Eddy et al., 2012). Eddy et al. (2012) also identify three limitations of face validity; 
firstly, it is unrealistic that patients move between states at fixed time intervals. Second, the 
medical evidence can be out-dated or misinterpreted and finally, the results can be 
manipulated to fit the wanted outcome if there are biased stakeholders.  
 
5.4  Cross-validation 
When comparing a study to similar studies and looking for similar results one is doing a 
cross-validation. Comparing across models and controlling that the results are similar, 
increases the confidence of the results (Eddy et al., 2012). If there is a high degree of 
dependency between the models the cross-validation becomes less valuable (Eddy et al., 
2012).  
 
5.5  Transparency  
The purpose of transparency is to make it easier for the reader to understand the non-
quantitative description of the model. Transparency gives a better foundation for readers who 
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want to evaluate the study at a higher level of both in mathematical and programming detail 
(Eddy et al., 2012). 
 
5.6  Predictive forecast 
The role of predictive forecast as a form of validation is not as important as the other forms 
previously mentioned. Nevertheless, this validation type controls the models ability of 
making accurate predictions of future outcome (Weinstein et al., 2003). Eventually one 
compares the predicted outcomes with the actual outcome (Eddy et al., 2012). 
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6 Material 
 
6.1 Ethical issues 
Ethical issues in medical research involve protecting human property. In a article by 
Rafiquddin (2006) it is stated that: “All research involving human subjects should be 
conducted in accordance with three basic principles (a) Respect to persons (b) Beneficence 
(c) Justice”. This refers to respect to autonomy and persons with reduced autonomy, to 
maximize benefits and minimize harms and lastly, to treat people according to what is 
morally right. In this thesis we have been concerned with anonymization of the data and 
using only data needed in order to construct the models. This does not involve any harm or 
moral issues in regards to the patients. We have been in contact with the Section of 
Information Safety and Privacy at OUS and followed the guidelines regarding anonymization 
and de-identification. 
 
6.2 Data set 
Below is a flow chart (Figure 10) to illustrate the processes behind the data set application. It 
is made in order for the reader to easily follow the steps behind data set process.  
 
Figure 10 - Flow chart (data set) 
 
MD Fløisand at OUS subtracted the data set from MedInsight and sensitive patient 
information was removed. The data was delivered in a SPSS file enabling us to read the 
different value labels (see Appendix G for a detailed view). The data was “cleaned” in Excel 
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by which we mean that unnecessary information (in terms of what we did not need in the 
analysis) was removed. For example, both patients with ALL and AML was received in the 
original SPSS file, whereas we only needed AML data. The original SPSS data set contained 
information from year 2000 to 2015. A few patients from 2015 were omitted based on the 
fact that there were so new that no remission, relapse or transplantation was registered on 
them. When removing patients who were diagnosed in 2015 and those suffering from ALL, 
we were left with a total of 307 patients in the data set. After the “cleaning of the data” we 
sorted the data in the order we preferred. MedInsight generates a patient number, which 
enabled to keep control of the patient’s events when pasting the SPSS information into new 
Excel sheets, before importing the data into Stata.  
 
The variables we used from the MedInsight extraction can be seen in Table 7 on the 
following page. 
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Table 7 - Data set variables from SPSS 
 
 
All variables containing dates were separated and each information day, month, and year 
were saved in new cells of their own. This was done to make it easier to create the time 
variables, discussed in section 6.3.1 “Time variables”. We also defined a variable “Gruppe 
+/-60” in order to split the group into two, according to their age (under or above 60 years).  
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Table 8 provides an overview of the variables created manually by the use of the information 
in the data set from SPSS.  
 
Table 8 - Data set variables (manually calculated) 
 
 
The date of birth is needed to calculate the age of the patients. Likewise, the dates of the 
different events were necessary to be able to trace the patient’s movements between states. 
This information is used to create time variables (explained in the section “Time variables”). 
 
6.2.1 Data set characteristics 
In this section we will provide a brief description of the data characteristics. This includes the 
mean age of the patients, and how many who receives induction treatment, transplantation 
and dies. The data set was divided by age (young and elderly), in order to see the difference 
of the age impact. 
 
The age distribution according to gender in the groups is shown in Table 9 below.   
 
Table 9 - Age of the patients in the data set 
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The oldest patient in the data set is aged 86, while the youngest is aged 16, on the date of 
diagnosis. Table 9 shows the mean age in both groups, among the genders. Females seem to 
be slightly older when receiving the diagnosis.  
 
A quick overview of the patients and the amount of people who receive treatment, 
transplantation and dies within a five-year perspective is shown in Table 10 below.  
 
Table 10 - Overview of induction treatment, transplantation and death (by group) 
 
 
In order to be eligible for transplantation the patient must reach complete remission. In the 
data set remissions is categorized either to be “full conditioning” or “reduced conditioning”. 
In Group 0 (< 60 years) 95 patients obtained “full conditioning” and the mean age is 42, 
ranging from 21 years to 59 years. Five patients had “reduced conditioning”. The age of these 
patients ranged from 24 years to 59 years. 
 
In Group 1 (≥ 60 years) five patients gained “full conditioning” and their age was between 60 
and 63, with a mean age of 61 year. In the same group eight patients had “reduced 
conditioning” and their age was between 60 and 68, while the mean age was 63 years. 
 
Table 11 - Transplantation in different remission states 
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In total, 110 patients in the data set received transplantation. This is about one third (36.8 per 
cent) of the entire cohort.  
 
Death 
The cause of death and time of death varies in this data set. There are 6 different values for 
death in the data set given. They are as follows: “Early death (<30 days after diagnosis)”, 
“Death without reaching remission”, “Death in first remission”, “Death in first relapse”, 
“Death in a later relapse” and “Death in a later remission”. This information is useful to 
calculate the amount of people in the decision tree that died or did not respond to the 
treatment. Death in all other states is based on transition probabilities.  
 
6.3 Expected values and outcome in the decision tree 
The input in the decision tree is given from the probability distributions and can be found in 
Table 12. These distributions are also used in the PSA. In order to be able to establish Alpha 
and Beta, the actual number of events in the data set was used. These probabilities are 
deterministic but in the model they are assigned probabilistic. The probabilistic approach will 
account for uncertainty in the parameters. 
 
Table 12 - Deterministic transition probabilities (decision tree) 
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The probability of ending up in the different branches in the tree is simply calculated in Excel 
by using beta and Dirichlet distributions.  
 
A screen print of how the expected values in the decision tree are calculated can be seen in 
Figure 11. 
 
The transition probabilities shown in Table 12 are added in each step accordingly in the 
decision tree, as one can see from Figure 13. To calculate the expected values we simply 
multiplied the different transition probabilities in the different branches. The red circles in 
Figure 11 indicate the calculation of the expected value. The column U in Excel picks up all 
of the probabilities, which is given by the probabilistic draw. To multiply all of the 
probabilities is the so-called roll back method. All of the different expected values are the 
starting point for our Markov models, respectively. All of the expected values sums up to 1. 
This assures us that all patients are distributed throughout in the tree.  
 
Figure 11 - Calculating the expected value (in Excel) 
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6.3.1 Time variables 
In order to implement time-dependency in the Markov models one has to create time 
variables. When time in remission is less than the time-span (five years) and no events have 
occurred, we allow censoring of the subjects. Ignoring censoring may lead to over-estimation 
of the hazard. The disease course determines what is considered a failure when coding the 
variables. The concept of failure is referring to whether an individual is experiencing an event 
during the chosen time-span. The time variables are given in months, therefore, January 2000 
is zero, February is one, and March is two, and so forth. This led us to 179 months, where 
December 2014 is month 179. The recoding was necessary to perform the survival analysis. 
 
 
Figure 12 - Excel extraction of time variables 
 
The extraction above (Figure 12) illustrates how “time in first remission” is calculated and 
coded. A bigger screenshot is available in Appendix E, in addition to a detailed description of 
how the time variables are calculated. The length of stay in first remission is equal to the time 
the first possible failure occurs subtracted by the time the patient achieved remission. The red 
circle illustrates a patient that has no failure, hence the time in remission is 60 months (five 
years) and the failure variable is coded as 0. In our data set we had right censoring. If an 
individual had less than 60 months left in the five-year perspective, it would be censored.  
 
6.4 Estimation 
Estimates were carried out in Stata. We started out by importing the time variable sheet from 
Excel into Stata. When the regressions were completed, we noticed that there were a lot of 
non-significant variables. Probably, this occurred since there are fewer observed events as we 
went from regressing those who leave from first remission to those who leave from first 
relapse. Table 13, 14 and 15 shows the Weibull regression output for model A1 (young), A2 
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(elderly), B (no response), C (palliative) and D (transplantation), with hazard ratios, standard 
errors, p-values, gamma (p) and 95 per cent confidence intervals.  
 
The regression output is significant if the p-value is below 0.05. Further, a hazard ratio above 
1 implies that the hazard increases with time, and opposite it decreases with time. If the 
confidence interval (of 95 per cent) contains 0, the null-hypothesis cannot be rejected, hence 
there are no statistical effects in the estimates.   
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Table 13 - Regression output for model A1 (young) and A2 (elderly) 
 
 
Table 13 displays the regression output from Stata for the different states.  
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When looking at the probability of going from first remission to relapse (TTRL) and 
transplant (TTTR), a one unit change in lnAge nearly three doubles the hazard of failure, 
whereas a one unit change in lnAge in first relapse (LIR), first relapse (Death) and second 
remission (TTTR) cuts the hazard with one-third, half, and one-tenth, respectively. In first 
remission (Death) a one-unit increase in lnAge will double by 19. This means that when a 
patient’s age increases, the hazard of failure will increase by 19. The p-value of first 
remission (Death) is non-significant (p = 0.1150), which means that the effect of age is non-
significant for dying in first remission. We can also see that the 95 per cent confidence 
interval is too large for this to cause an effect. The p-values for first remission (TTRL), first 
remission (TTTR), first relapse (LIR) and second remission (TTTR) are all significant. This 
means that all these transitions are affected by age. First relapse (Death) and, as mentioned, 
first remission (Death), with a p-value of 0.248 and 0.1150 respectively, is not affected by 
age. In first remission (TTRL), first remission (TTTR), first remission (Death) and second 
remission (TTTR) all hazards are decreasing. We can see this by looking at p, where all these 
transitions are below zero. In first relapse (LIR) and first relapse (Death) p is equal to 1.1137 
and 1.2392 respectively. This means that the hazard is growing over time. ln_p is just the 
natural logarithm of p, and hence they reflect the same.  
 
Table 14, on the following page, shows regression output for model B (no response) and 
model C (palliative care).  
 
The hazard ratio in model B (no response), Table 14, is approximately one-third (0.3886), 
which means that a one-unit change in age will cut the hazard of failure by one-third. We can 
also see that the p-value is non-significant (0.2300), hence, age has no effect on dying. The p 
is above one, which means that the hazard is growing over time. In model C (palliative), a 
one-unit change in age will increase the hazard of failure by 1.1452. Here, the p-value is non-
significant (0.9220); and we may deduct that age has no effect of dying in palliative care. p is 
almost one (0.9686), therefore the hazard is decreasing over time but are close to being 
exponentially distributed.  
 
  59 
Table 14 - Regression output for model B (No response) and C (Palliative) 
 
 
Table 15 - Regression output for model D (Transplantation) 
 
 
In Table 15 we can see that the hazard ratio of remission (TTRL) is approximately cutting the 
hazard of failure by a half. The p-value is non-significant (0.4690), which means that the 
effect of age in remission (TTRL) is not significant. Since p is 1.3853, the hazard of failure is 
increasing over time. From transplant/remission to death, the hazard ratio is 1.2349. This 
means that a one-unit increase in age will increase the hazard of failure. The p-value is non-
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significant (0.7860), showing that age has no effect on dying in transplantation/remission. p 
is close to one, which makes the hazard of failure decreasing, but it is close to being 
exponentially distributed.  
 
Probabilistic transition probabilities 
In Table 16 one can see an extraction of the transition probabilities estimated above and by 
use of the Cholesky decomposition, which is used in the Markov models (A1, A2, B, C and 
D). The first four cycles and every tenth cycle from ten to 60 are included. This is done to 
draw a picture of how the transition probabilities change over time. In the Excel model all 
cycles are included with different probabilities for each cycle (see Appendix I). It is 
important to note that these transition probabilities are made probabilistic in our analysis, and 
because Excel conducts draws whenever something is copied and pasted, these probabilities 
are not from the same draw.  
 
Table 16 - Transition probabilities (Markov models) 
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The transition probability in first remission, model A1 (young) for time to relapse, decreases 
over time. This means the longer you stay in remission the more likely you are to avoid 
relapse. This is similar for time to transplant and death in remission due to the same causes.  
 
In Model B (no response) and C (palliative), the transition probabilities increase over time. 
This is due to the fact that the patients only receive palliative care and death is the only state 
they can transit to. As already described in the Background chapter, untreated AML is deadly 
and the life expectancy is short.  
 
For patients who receive transplantation, the probability of having a relapse and dying is 
decreasing over time. This can be explained by the fact that the post-transplantation phase is 
similar to being in remission, however transplanted patients have a higher risk of dying 
during the near future after transplantation. 
 
Graphs of the probabilistic transition probabilities 
We added the probabilistic transition probabilities in several Figures (Figure 13, 14, 15, and 
16) to capture the difference in leaving the different states among young and elderly. 
Additionally, we wanted to compare palliative care against “no response” to see if there are 
any differences, since they receive the same treatment in Markov model B and C. 
Transplantation is also explored to illustrate that patients in early stage of transplantation has 
a higher probability of relapse or death. All figures are shown in an 18 months perspective. 
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Figure 13 - Transition probabilities in model A1 (young) and A2 (elderly) 
 
Figure 13 illustrates the probabilistic transition probabilities for “leaving 1st remission” in A1, 
“1st remission to 1st relapse” in A1, “leaving 2nd remission” in A1, and similar for A2. We can 
see that the probability of leaving second remission in model A1 is much higher than in A2. 
A reason may be that younger patients will receive transplantation more often than elderly 
patients. The probability of experiencing a relapse is lower in younger patients than elderly. 
This is reasonable since younger patients often have a better prognosis than elderly. We can 
also see that the probability of leaving first remission is lower in young patients than the 
elderly.  
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Figure 14 - Transition probabilities in Transplantation 
 
 
Figure 15 - Transitions probabilities in model A1 (young) and A2 (elderly) to Transplantation 
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Figure 14 shows that in the first couple of months after transplantation, there is a great 
probability of leaving this state to either relapse or death. This probability is smoothing out 
and decreasing after a while. Remission to relapse is very low and has a slight increase over 
time.  
 
Figure 15 shows the transitions to transplant from model A1 and A2. In model A1 and A2 the 
probability of going from remission to transplant is higher in second remission than in first 
remission. Model A2 has an overall lower probability of going from remission to transplant. 
The probability of leaving to transplant decreases over time. 
 
 
Figure 16 - Transition probabilities in Palliative care and No response 
 
In Figure, 16 No response and palliative care, illustrates the transition from treatment to 
death. We can see that “No response” has an increasing curve as time goes by, while 
“palliative care” is slightly decreasing.   
 
6.4.1 Time-independent probabilities 
To compensate for too few patients in the long run and to calculate precise transitions 
probabilities for each cycle, we had to make some simplifications. The transition from second 
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remission to second relapse, from second remission to death and the probability of leaving 
relapse in transplant to death, was calculated by using the instantaneous event rate explained 
in the Method chapter. Table 17 shows these probabilities. 
 
Table 17 - Time-independent probabilities (Markov models) 
 
 
Second remission to relapse (TTRL) is used to indicate those who leave from second 
remission to second relapse. Further, it is used in second relapse to indicate those who enter 
this state from second remission. Second remission to death is used as a constant probability 
of dying in second and third remission. Relapse in transplant to death is used as a constant 
probability of dying in transplant/remission and relapse.  
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6.5 Costs 
6.5.1 Overview 
Figure 17 is a flow chart describing the different cost input sources and which costs we had to 
process in order to make them accurate for our purpose.  
 
Figure 17 - Flow chart (costs) 
 
In order to calculate the costs of treatment in the decision tree, each form of chemotherapy, 
including the price of the subsequent hospital stay, type and price of medications and the 
price of diagnosis had to be identified. For the Markov models the cost of being in remission, 
which is the price of follow-up, price of consolidating chemotherapy, and the cost of new 
treatment in relapse had to be identified. Similar, the cost of transplantation and the 
subsequent follow-up had to be identified. For the patients who only received palliative care 
the price of this had to calculated. All of the costs mentioned above is defined as resource use 
and were tracked with help from the accounts department of the Haematology ward, in 
addition to costs reported directly from the ward staff (expert opinion). The cost of 
transplantation is found in a article by Mishra et al. (2002) where they identified the cost for 
this in Norway. The cost of palliative care, offered at local hospitals, is found by the DRG-
price for palliative care. All of these costs are a part of the treatment course and important for 
the overall picture of AML.  
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The costs are estimated from the health care provider’s perspective. Throughout the analysis, 
we chose to use costs in 2014 NOK, because these were the year of fixed cost given to us by 
OUS. However, the cost of chemotherapy, blood and medications was given in 2015 NOK, 
and were adjusted (by using a CPI calculator). All costs are given a gamma distribution with 
a standard error of 20 per cent. 
 
There are two bar charts (Figure 18 and 19) following the costs related to induction and 
further treatment, respectively. These are only meant to give a visual picture of the resource 
allocation, and are based on Table 21 and 22. 
 
6.5.2 Fixed costs 
The cost variables we received from the Haematology ward contains a post named “Raw 
materials” and this includes different equipment such as needles, patches and sterilisation 
material. The post named “Revenue” is including courses and lectures held by the ward, 
employee leasing programs and positions partly waged by the University of Oslo. Table 18 
shows the total cost at the Haematology ward (excluded medicaments): 
 
Table 18 - Haematology ward costs (2014) 
 
 
To make the cost more accurate for the AML patients, we removed the cost for the average 
blood transfusions at the Haematology ward and created a new variable with the actual 
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average cost for AML patients. The cost of length of stay is NOK 7634 per day without blood 
transfusions. This is calculated by using the total cost found in Table 18 (excluding the 
internal transactions) and dividing it by the number of inpatient days at the Haematology 
ward which was 8 894 in 2014 (see Appendix K for details).  
 
Blood transfusions  
To be able to calculate the cost of transfusions, we need a representative picture of the 
average amount of transfusions for patients treated. The average figures were produced by 
MD Fløisand. Next we added the price for the different blood products, and multiplied with 
the average amount of transfusions for each chemotherapy treatment. This is illustrated in 
Table 19: 
 
Table 19 - Blood prices and quantity (OUS) 
 
 
The variables for thrombocytes and erythrocytes were added directly in each model. The cost 
for blood transfusions is given by the Blood bank at OUS Ullevål. 
 
Estimated medical costs 
MD Fløisand identified all of the medications involved in the different treatment strategies, 
while the accountant department gave the price for each medication. The list of medicaments 
from MD Fløisand consisted of 17 different medicaments; antibiotics, penicillin, medications 
against fungal infections, nausea reducing drugs, liquid transfusions such as nutrition and 
sodium chloride, diuretics, pain relievers and sleep medicine. The calculated average of these 
medications are implemented in the induction treatment. The chemotherapy is not included 
here (see section “Induction treatment costs” and “Further treatment costs”).  
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Some medications, such as medications against fungal infections are very expensive, and 
there is approximately one in twelve patients receiving this. MD Fløisand estimated an 
average dosage per patient. Table 20 shows the different medications given with associated 
costs per patient. See Appendix F for full price list from OUS and explanation of the 
calculation behind the average costs per patient. 
 
Table 20 - Medications used in induction treatment (OUS) 
 
 
Antiemetic is a drug that reduces nausea, antimyotics is a drug against fungal infections, 
hypnotic is a drug that helps the patient sleep, analgesic is used against severe pain, and 
proton pump inhibitor is used to drain out the leukemic cells after chemotherapy. Antibiotics 
are given to almost all patients because of the high risk of infection (Fløisand, 2015).   
 
6.5.3 Induction treatment cost 
The costs associated with induction treatment in the decision tree are shown in the Table 21, 
on the following page. The costs that incur in the decision tree are the first and second 
 70 
chemotherapy, length of stay, blood transfusions, diagnosis, intensive care unit, and total 
average of the medication cost. 
 
Table 21 - Unit cost and cost per patient (decision tree) 
 
 
MD Fløisand counted the length of stay for the different chemotherapies. The length of stay 
is 40 days in Table 21, to capture the cost of the patients who stays at hospital during 
induction treatment for more than 30 days. It is based on the average of the patients from 
2014 and ensured to be representative for the entire data set. The dosages of medications are 
given in milligrams and multiplied with the average body surface of the patients from 2014. 
The average body surface of these patients is 1,92 m2 (Fløisand, 2015). The patients receive 
chemotherapy over a period of time. Cytarabine is given each day for seven days, while 
Daunorubicin, Idarubicin and Amsakrin are given each day for three days. Ara-C+I is a 
combination of Cytarabine, Cytarabine maintenance, and Idarubicin, which has a total cost 
per patient of NOK 37 180. Ara-C+D is a combination of Cytarabine, Cytarabine 
maintenance and Daunorubicin, which has a total cost per patient of NOK 67 458. Those 
patients receiving a third option of chemotherapy (Other cytostatic) is estimated as a mean of 
Ara-C+I and Ara-C+D. Cost per patients shows the pathway cost per individual when 
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receiving the diagnosis and treatment. The costs that are conditional on treatment are 
chemotherapies and blood tranfusions. 
 
The cost of diagnosis is based on expert opinion from the Haematology ward. It includes 
doctor hours spent, equipment used, and laboratory testing. In the cost calculation no use of 
nurses is included, nor are fixed cost.  
 
The intensive care unit reported (expert opinion) the cost for a hospital stay to be 
approximately NOK 55 000 per day. Around five per cent of the total number of AML 
patients receives intensive care at the intensive care unit. This percentage is added in to the 
chemotherapy treatments. 
 
Figure 18 below shows the costs in the decision tree and one can easily tell that length of stay 
is the greatest cost driver.  
 
 
Figure 18 - Bar chart of costs related to induction treatment. 
 
6.5.4 Further treatment (Markov models) 
Further treatment costs involves Markov model A1, A2, B, C, and D. The costs identified in 
the Markov models can be seen in Table 22.   
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Table 22 - Unit cost and cost per patient (Markov models) 
 
 
As mentioned before, patients who enter the Markov models are those who come from the 
decision tree. Patients that do not receive transplantation, go to relapse or die, will receive a 
third chemotherapy (see the HOVON map in Appendix J). The cost of the third 
chemotherapy will therefore incur in cycle one in first remission, in the Markov models A1 
(young) and A2 (elderly), since those who enter the Markov model in cycle zero are those 
who enter directly from the decision tree. In cycle one the costs will therefore be cost of third 
line chemotherapy, length of stay at hospital, intensive care, blood transfusions, and 
medications associated with treatment. After this cycle there are only costs of follow-up that 
incur. For second and third remission follow-up is the single occurring cost.  
 
Follow-up is estimated at every month for one year. The second year, they are followed up 
every third month for another 12 months. At year three, they are followed up once every 
sixths month for the rest of the observational period. Cost of follow-up is based on estimates 
from MD Fløisand, by using the average wage of a chief attending physician at the 
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Haematology ward. The equipment used and the price of laboratory testing is approximately 
NOK 500, and the physician hours spent is about one hour per follow-up (see Appendix N for 
wages of the ward). Hence the cost of follow-up per patient in Table 22 is NOK 1 343. 
 
In relapse, a patient will receive either a combination of Mitoxantron, Cytarabine and 
Amsakrin (chemo in relapse), or the first chemotherapy (as in the induction treatment). 50 per 
cent of the patients will receive first chemotherapy, while the other 50 per cent will receive 
“chemo in relapse” (Fløisand, 2015). Since first chemotherapy contains three different 
chemotherapies, we have taken a mean of AraC+Dauno and AraC+Ida. This is a 
simplification, assuming that it is an equal probability of receiving either one of them. Since 
“other chemotherapy” is a mean of the other chemotherapies, we used this. These patients 
will also receive a combination of the medications connected to treatment as well as cost of 
blood transfusions, intensive care, and the cost of length of stay.  
 
Palliative care 
The cost of receiving palliative care is found by using a general DRG (Diagnosis-related 
groups) for outpatient palliative care in addition to adding the cost of blood transfusions. The 
average outpatient visits are three times per week, while the frequency of blood transfusions 
is twice a week (expert opinion). DRG is a patient classification system where hospital stays 
(or outpatient consultation) in somatic institutions are classified in groups that are both 
medical and resource allocated homogeneous (Helsedirektoratet, 2015a). The DRG weight 
for the different diagnosis is supposed to reflect the cost of treatment. 
 
The local hospitals administer the patients receiving palliative care. The accountant 
department at OUS have no data concerning costs for this group of AML patients. To be able 
to calculate costs for this group we chose to use the DRG price for outpatient palliative care 
in combination with the cost of blood transfusions. The DRG weight is 0,132 
(Helsedirektoratet, 2014), and DRG price in Norway was NOK 40 772 in 2014 
(Helsedirektoratet, 2015b). When multiplying this we get a cost of NOK 5 382 per day. 
Hence, the cost of each cycle in model B (no response) and C (palliative) is 10 (every third 
day) multiplied by the cost per day, which is NOK 53 820 per cycle. The cost of blood 
transfusions (a combination of erythrocytes and thrombocytes) is NOK 43 160 per cycle. 
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Transplant 
Number of days of follow-up in transplant is estimated in collaboration with MD Fløisand. 
When a patient has undergone transplantation, he/she is discharged at day 35, approximately. 
The patient is then followed up three to five days per week, in two weeks. Then for two to 
three days per week in four weeks, once per week in eight weeks, and lastly, once per two 
weeks for one year. The patients are followed up approximately two times per year. In the 
article by Mishra et al. (2002) it was reported that the cost of one-year follow up was $14 
553, which is NOK 145 534 in 2014. We assumed that his calculation was based on what MD 
Fløisand told us about how often they were followed up. Our estimation is therefore the cost 
of follow up divided by 1/12. This is a simplification because the intensity of follow up is 
higher in the first months after transplantation. After one year the patients are usually 
followed up at local hospitals. We used the estimated follow-up cost from remission in model 
A1 (young) and A2 (elderly) in the remaining cycles.   
 
Table 23 - Transplantation costs (in US $ and NOK) (Mishra et al., 2002) 
 
 
The costs of transplantation reported via Mishra et al. (2002) are adjusted to represent the 
cost in 2014 by using the consumer price index inflation calculator from Bureau of Labor 
Statistics (Bureau of Labor Statistics, 2015) and then converting the US Dollar to NOK 
(Currency Converter, 2015). The final stage was to use the “Consumer price index” function 
on the Statistics Norway web page, to represent the costs in 2014 NOK (Statistics Norway, 
2015). 
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Figure 19 - Bar chart of costs related to further treatment (Markov models) 
 
Figure 19 is a bar chart of the costs added in the Markov models. Transplantation is clearly 
the highest cost, but the intensive care is also a significant cost driver.  
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7 Results 
 
The outcome of this analysis is a five-year survival of patients with AML, as well as the total 
cost of treatment. The model predicts the numbers of individuals who receives the different 
forms of treatment in addition to the price of the treatment and remission paths. All costs 
were discounted, except for the costs in the decision tree. 
 
In order to conduct the PSA with 1000 iterations a Monte Carlo simulation was carried out in 
Excel by using Visual Basic. The expected costs and life expectancy in the models were 
investigated both isolated and as a total including the decision tree. The isolated analysis 
displays the result independent of the decision tree, which captures the total cost and life 
expectancy of the individual Markov models. The analysis including the decision tree takes 
the pathway into consideration to illustrate the total life expectancy and costs dependent of 
age and those responding to treatment. The PSA reflects the cost and life expectancy per 
individual. The results of model A1 (young) and A2 (elderly) includes transplantation, while 
the results reflecting the decision tree is denoted as induction treatment. 
 
The results confirmed that AML treatment is resource demanding and there is considerable 
variation with respect to patient characteristic, clinical pathway and prognosis.  
 
Table 24-29 shows the PSA result per individual in our data set. Scatter plots of cost per life 
expectancy resulting from the Monte Carlo simulation is shown in Figure 20-25.   
 
7.1 Expected costs and survival 
Table 24 refers to patients responding to treatment in the decision tree, which then goes 
through model A1 or A2, and receives transplantation. Palliative care includes patients who 
receive palliative care through either not responding to or not receiving treatment from the 
decision tree. Total young and elderly patients is all models combined, separated by age only. 
The total of the PSA results are all models combined.  
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Table 24 - Discounted costs per individual in all models with the decision tree  
 
 
Table 24 displays the expected cost per individual. Total cost ranged from NOK 1 026 551 to 
NOK 1 792 015. Among the young patients, the total cost ranged from NOK 872 552 to 
NOK 1 393 314, while the total cost for the elderly patients ranged from NOK 153 999 to 
NOK 398 701. The cost of the young patients responding to treatment ranged from NOK 944 
626 to NOK 1 646 926, while the cost of the elderly patient group ranged from NOK 556 352 
to NOK 1 246 656. The cost of palliative care in young patients ranged from NOK 69 093 to 
NOK 309 769, whereas the cost of palliative care in elderly patients ranged from NOK 125 
568 to NOK 1 093 547. The total cost of all models combined has a mean of NOK 1 401 521. 
 
Table 25 - Discounted cost per individual in Markov models with the decision tree  
 
 
Table 25 shows the PSA results of the decision tree and the Markov models. The least costly 
treatment incur in patients who do not receives induction treatment (model C), while the 
highest cost incur in the model A1 for the young patients. This is NOK 53 129 and NOK 639 
267, respectively. There is a substantial difference in cost between model A1 (young) and A2 
(elderly), where the mean cost is NOK 639 267 in model A1 and NOK 123 436 in model A2. 
This is similar for induction treatment where the mean cost of young patients is NOK 426 
648 and the cost of elderly patients is NOK 83 303.  
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Table 26 - Life expectancy per individual in all models with the decision tree  
 
 
In Table 26, the total life expectancy ranged from 26.61 months to 46.10. The total life 
expectancy of the elderly and young patients ranged from a mean of 5.59 months to 32.02 
months. Response among young patients is slightly higher than in the total for young 
patients, with a mean life expectancy of 39.89 month and 32.02 months respectively. The 
total mean life expectancy for all models combined was 37.61 months.  
 
Table 27 - Life expectancy per individual in Markov models with the decision tree 
 
 
In Table 27, the life expectancy in the Markov models ranged from 0.21 months for elderly 
patients who did not receive induction treatment to 30.67 months for model A1 (young). The 
survival in model A1 (young) is considerably higher than in model A2 (elderly), whereas the 
mean life expectancy in model A1 is 30.67 months and 4.72 months in model A2. The mean 
survival in the palliative treatment is 0.79 months for the patients who did not respond to 
treatment and 0.48 months for patients not receiving induction treatment.  
 
The scatter plot in Figure 20 illustrates the relationship between cost per life expectancy of 
the young and elderly patients. Young patients has a better result in terms of life expectancy, 
but at a higher cost, where the average life expectancy is around 35 months and the average 
cost is just below NOK 1 200 000. Elderly patients shows lower costs with a poorer life 
expectancy compared to the young patients.  
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Figure 20 - Total cost per life expectancy in young and elderly 
 
Figure 21 shows a scatter plot of patients receiving palliative care. The cost increases along 
with the patient’s life expectancy. It is important to notice that the x-axis ends in 12 months; 
hence the life expectancy in palliative care is quite low. The average life expectancy is 
around 4 months for the elderly patients, and 1 month for the young patients. This might be 
due to that more elderly patients receive palliative treatment. 
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Figure 21 - Cost per life expectancy in total palliative care 
 
 
Figure 22 - Cost per life expectancy in response 
 
Figure 22 illustrates a scatter plot of young and elderly patients who responds to treatment. 
The cost per life expectancy is higher in young patients than in elderly patients. For young 
patients, the life expectancy has an average of nearly 40 months. Elderly patients have both a 
shorter life expectancy, ranging between 20 and 25 months, and lower costs. 
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Figure 23 - Cost per life expectancy in no response and no induction treatment 
 
In Figure 23, the cost per life expectancy is increasing for patients who did not receive any 
induction treatment and patients who did not respond to treatment. Patients with no induction 
treatment starts off with both lower costs and life expectancy than patients that did not 
respond to treatment. Both models have the same treatment costs. Yet, they differ slightly in 
cost and life expectancy, which may be due to different transition probabilities as they belong 
to different Markov models. 
 
The tables below show the PSA results of receiving the specific forms of treatment. By this 
we mean that all Markov models are starting in one and then distributed out in the model, 
using the calculated transition probabilities. This is performed to express the isolated results 
for each model.  
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Table 28 - Discounted cost per individual in Markov models without the decision tree 
 
 
In Table 28 the mean cost of model A2 (elderly) is somewhat higher than in model A1 
(young), and the result is NOK 999 995 and 917 789 respectively. Patients with no response 
to treatment have a mean cost of NOK 574 975, whereas patients who did not receive 
induction treatment have a mean cost of NOK 799 392.  
 
Table 29 - Life expectancy per individual in Markov models without the decision tree 
 
 
Table 29 shows the life expectancy of all Markov models. Markov model A1 (young) has a 
mean life expectancy of 47.27 months, whereas Markov model A2 (elderly) has a life 
expectancy of 41.11 months. The model of patients with no response to treatment has a 
poorer life expectancy (6.15 months) than the model of patients who did not receive 
induction treatment (7.54 months). The difference is not substantial.  
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Figure 24 - Cost per life expectancy in model A1 and A2 without the decision tree 
 
Figure 24 illustrates the relationship between cost per life expectancy in Markov model A1 
(young) and A2 (elderly). Model A2 has a somewhat higher cost than model A1, but at a 
shorter life expectancy. Life expectancy in model A2 range from approximately 30 months to 
almost 50 months at cost ranging from NOK 700 000 to around NOK 1 300 000. 
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Figure 25 – Cost per life expectancy in “no response” and “no induction treatment” without the decision tree 
 
In Figure 25, the cost and life expectancy of patients who did not receive induction treatment 
is visibly higher than for patients who had no response to treatment. Cost per life expectancy 
is increasing over time in both models.  
 
Cost per cycle in all Markov models 
Figure 26 below shows the costs incurring from cycle zero to 18 in Markov models A1 
(young), A2 (elderly) and transplantation. The costs are evidently highest during the first 
couple of months, with model A1 generating the highest costs. It dramatically decreases past 
cycle two, below the costs of transplantation. This is because the consolidation therapy 
(including length of stay, medications, ICU etcetera) occurs only in the first cycle in Model 
A1. The cost of transplantation is higher during the first months because the transplantation 
in itself is very costly.   
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Figure 26 - Cost per cycle in cycle 0-18 for A1 (young), A2 (elderly), and transplantation 
 
In Figure 27, on the following page, the cost per cycle is highest during the first cycles. It 
decreases consequently until cycle nine, where it partly flattens out, and further it is 
stabilizing in the later cycles. The cost per cycle is highest for patients who had no response 
to treatment during all cycles, except for a peak at cycle one for patients who did not receive 
induction treatment. Cost for patients who did not respond to treatment initiates below NOK 
10 000 at cycle zero, and terminates at below NOK 1 000 in cycle 18. The cost of patients 
who did not receive induction treatment starts below NOK 6 000 in cycle zero, has a peak in 
cycle one at below NOK 8 000, and ends at zero cost in cycle 18.  
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Figure 27 - Cost per cycle in “no induction treatment” and “no response” in cycle 0-18 
 
7.2 Comparing results to the UK 
In order to be able to compare our results to the study by Wang et al. (2014), we had to adjust 
the cost in terms of purchasing power. Purchasing Power Parities (PPP) are currency 
converters, which take account of the effects of differences in price levels between countries. 
PPPs make volume comparisons of Gross Domestic Product (GDP) components and 
comparisons of price levels. A PPP show how many units of currency A needed to be spent 
in country A in order to attain the same volume of a product in currency B in country B 
(Koechlin, Lorenzoni, & Schreyer, 2010).  
 
In a paper by (Koechlin, Konijn, Lorenzoni, & Schreyer, 2014) we found that the hospitals 
price level is 207 for Norway and 119 for the UK. The EU average is 100. By dividing the 
price level of the UK by the price of Norway we found that UK has a purchasing power of 
57.5 per cent relative to Norway.  
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Table 30 - Cost and life expectancy in Norway and the UK 
 
 
Table 29 shows the comparison of our results to the results of Wang et al. (2014), adjusted 
for purchasing power of 57.5 per cent for health care (Koechlin et al., 2014). From this table 
we can see that the total cost is higher in Norway opposed to the UK. The difference in total 
cost between our study and the UK is approximately 35.7 per cent, where Norway has higher 
costs. The cost of young patients in the UK is higher than in our study, with a difference of 
30.8 per cent. For elderly patients there is a difference in costs of nearly 122.9 per cent, 
where Norway spends more than the UK. Overall, Norway predicts a greater life expectancy 
compared to the UK.  
 
7.3 Validation of the research 
The decision tree and the Markov model are validated according to internal validity, external 
validation, face validity, cross-validation and transparency.  
 
7.3.1 Internal validation 
This study is conducted by two persons and has therefor been controlled and discussed 
regularly. Additionally, our supervisor Eline Aas has controlled the formulas and the work 
along the way. In order to control that the Markov models are correctly built we added a 
“Control” column at the end of each model where one easily could tell if the entire cohort 
was distributed throughout the rows. There are five separate Markov models in Excel; 
Markov A1, Markov A2, Markov Transplant (D), Markov Palliative (C) and Markov No 
response (B). Together with the amount of people who dies in the decision tree all of these 
models should sum up to 1 for each cycle. To control for this we made a new sheet in Excel 
where we added each value for all of the “Control” columns of the respective models in 
addition to the “Early death” from the tree. (A screen shot of the Control sheet in Excel can 
be seen in Appendix D.) All of the rows sums up to 1, which is an internal validation of the 
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models. By having the control columns in each of the Markov models it was easier to debug 
the model since we could see which rows that did not sum up correctly.  
 
7.3.2 External validation 
Our output from the study can be compared to the numbers from the Cancer Registry, and if 
our model corresponds to the reported survival one can say that it is externally validated. If 
our results correspond to the anticipated results this is an important validation and strength of 
the model. 
 
Figure 29 illustrates the difference of the five-year survival in our data set and our estimated 
model compared to the cancer registry numbers from 2004 to 2008 and 2009 to 2013.  
 
 
Figure 28 - Comparison of five-year survival in (external validation) 
 
Our data set indicates a better survival than the Cancer registry data. The Weibull model is 
higher than all other curves in the graph, but it goes below both our data set and the Cancer 
registry (2009-2013) curve between years four and five. Our model did not demonstrate a 
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good fit compared to the empirical data. The predicted survival did not match the empirical 
curve, except for the first and last years of the time perspective. This might be due to a low 
mean age in our data set.  
 
7.3.3 Face validation 
The AML study is conducted in collaboration with a specialist doctor at the Haematology 
ward at OUS Rikshospitalet and the model has been constantly discussed with him. This 
gives face validity. Since the framework for this thesis has been worked out together with 
MD Fløisand he has controlled that the decision tree is correct and that the use of the 
variables in the data set is correct. He has also ensured that the medical strategies have been 
interpreted correctly. To correct for the unlikelihood that patients move between states at 
fixed time intervals the cycle length is only one month. He also controlled that we included 
the correct chemotherapies, blood transfusions and other medicaments. An important factor 
of face validity is that the expert can recognise the actions in the model, which is confirmed 
by MD Fløisand. The study by Wang et al. (2014) is also a form of face validation, as the 
structure of our models is based on this paper. The structure of their model corresponds well 
with our data set. 
 
7.3.4 Cross-validation 
The foundation of our AML study is based on a previous study from the UK by Wang et al. 
(2014), which may be considered as cross-validation, as the studies are examining the same 
topic. However, our results appear not completely comparable to the UK model, because the 
groups are not entirely corresponding, nor are the results reported identically. However, the 
clinical pathway is equal in both studies. The life expectancy and costs varies between 
Norway and the UK, but this can also be subject to different inclusion criteria’s.  
 
7.3.5 Transparency  
The study is transparent as all of the methods are available and explained in the Method 
chapter. It shall be possible to replicate this study if one is given the data. The do-file from 
Stata can be seen in Appendix N. We have also included several screen prints from the 
Markov models in Excel in the appendices (Appendix A, B and C), which mean that one 
ought to be able to rebuild the model based on these. The calculation of the costs has been 
through roughly discussed in the Material chapter and should be easy to recalculate. 
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7.3.6 Predictive forecast 
The study can be used in prediction of the outcome of treating AML patients, both in relation 
to survival in different states, as well as the cost for treatment in Norway, but to conduct a 
predictive forecast would not be possible as no time has passed, and it is impossible to 
control that the results are valid in the future. 
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8 Discussion 
 
8.1 Main findings 
Both costs and life expectancy varied according to the initial treatment and the age of 
diagnosis. The results of our models indicate that the total life expectancy is 37.61 months, 
while the expected total cost is NOK 1 401 521. 
 
As expected, younger patients have a higher life expectancy and incur more costs than elderly 
patients. However, in the PSA result when not including the decision tree, the cost of model 
A2 (elderly) is higher than model A1 (young). This might be caused by elderly patients 
having a higher probability of leaving remission to relapse than young patients. In relapse, 
patients receive an additional chemotherapy, and since elderly patients have a higher 
probability of relapse, the costs will increase.  
 
It is interesting to compare the survival and costs in Norway and the UK. In the UK more 
elderly patients was included, which might make a comparison unfeasible. However, since 
the UK study separates responding to treatment with early response and late response, the 
variation from our study should be interpreted with precaution. The UK study used register 
data from the Haematological Malignancy Research Network (Wang et al., 2014) while we 
used individual data. It may be an advantage of their study that specific registry data is used 
to model AML, whereas our study has the advantage of using individual data. On this basis, 
the studies appear comparable.  
 
8.2 General 
New and improved methods may affect the results both in relation to survival and costs. One 
could use the results to rank the least and most costly treatments, but this would not be a 
suitable foundation for economic evaluation since it involves different risk groups. Further, if 
one wanted to use this study as a basis for decision making one would need to apply some 
more details to the model, such as the utility measure “Quality Adjusted Life Year” 
(QALYs), and a threshold for willingness to pay. The societal perspective should be 
considered as well. Nevertheless, it was beyond the scope of this study to compare the 
economic impact of the different treatment strategies. 
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In the case of AML there are no pre-determined ways of treating that will be the best 
treatment strategy. Rather, the purpose is to treat with a curative goal for those patients that 
may have a possibility of handling heavy treatment. This individual customization makes it 
difficult for the modeller to build a model that reflects this patient group true clinical 
pathway. Much work has been put into making the model as accurate as possible. The 
validation of the model is conducted to control for this.  
 
Weinstein and Stason (1977) discuss that the estimates of medical effectiveness and cost used 
in analysis ought to express and reflect explicitly the uncertainties surrounding the estimates. 
The sensitivity analysis is conducted to correct for the uncertainty, but some strengths and 
limitations will be discussed further in next sections.  
 
We chose not to discount life expectancy because it does not make any sense that “using” 
less health now will give a benefit of more health in the future. It is argued that comparing 
the size of the health loss is easier when using undiscounted units in prioritizing health 
interventions (NOU 2014: 12, 2014).  
 
8.3 Strengths and limitations 
 
Material 
As mentioned in the Method chapter, we had to make some simplifications along the way. 
This study only looks at AML as a distinct cancer form, and does not look at the difference 
between primary and secondary cases. We did not differentiate between primary and 
secondary cases due to the number of people in the cohort. If we did so the results could be 
misleading since there are too few individuals in the secondary group. Nevertheless, if 
possible, one should separate these two forms in order to get a more accurate picture of the 
transition probabilities and life expectancy. 
 
The study does not look at other hospitals than OUS Rikshospitalet. Inclusion of patients 
from other hospitals that actively treat AML patients could have given other results. MD 
Fløisand suggested that there are elderly patients in local hospitals who also have the AML 
diagnosis, but are not actively treated for the disease. A reason for this might be comorbidity 
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and the fact that they would not handle the heavy chemotherapy treatment. Still, this does 
affect the results, as they are not accounted for. 
 
Another factor is that the patients are divided into two groups; under 60 years or 60 years and 
older. This means that the model is not completely age specific. At OUS Rikshospitalet the 
treatment line differs between patients at the age of 65, rather than 60 years, which we have 
used in our model. This “manipulation” was done for two reasons; firstly, this is the 
subdivision used by Wang et al. (2014) in their study and what we wanted to compare our 
study to. Secondly, there were not many patients in the older group if we divided the group at 
the age of 65, and this would lead to non-significant results in the regression analysis.  
 
Our data set consists of individual data subtracted for our specific research. This can be found 
as strength of the study compared to register data where one has a large data set unspecified 
for specific research. 
 
Time frame 
The time frame of this study was set to five years. It is common to use a three or five-year 
perspective in cancer research, and in this relation it was natural to adopt a five-year time 
frame. A drawback by only following the patients for five years is that some patients 
experience more than two relapses, and this will not be captured in our model. On the other 
hand, there are not many patients who experience this; therefore it would not make any huge 
impact on the results. 
 
Probabilities 
Due to few patients left in the cohort after the first relapse, it was not possible to calculate 
any transition probabilities by using Weibull regression. We had to make simplified 
probabilities for the states that occurred after second remission. These adjustments should not 
have any huge effect on the results. We assumed that the second relapse is equal to the first 
relapse in relation to the transition probabilities and treatment costs. There were not many 
patients in the data set that had a second relapse, nor third remission, and hence it was 
difficult to make individual calculations for these patients.  
 
We preformed many commands in Stata to get a full picture on how the data set looks like 
and how the regressions would compare. Many of the regressions are not significant, which 
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may be due to few numbers of patients in the cohort. We assumed that the size of the cohort 
was the main reason for the non-significant regressions; hence we chose to accept the 
regression output.   
 
In our study we over-estimate survival because half-cycle correction is not been incorporated. 
Since we are only looking at the clinical pathway it might not be necessary to adjust for this, 
but in an economic evaluation study it could be important.  
 
Costs 
The costs have been identified at an average level, and should reflect the average cost of an 
AML patient. Through the PSA we know that the results vary to some degree. This makes 
sense as the treatment course can involve everything from only receiving palliative care or 
transplantation.  
 
Another perspective, which is not included, is the cost of patients who achieve remission, but 
continue their lives with complications or side effects from the treatment. These patients can 
still be costly if they have follow-ups exceeding the five years we investigated and if they are 
unable to go back to work (partly or completely).  
 
Patient involvement is becoming a greater part of the health care, and the cost of this may be 
difficult to include, but from a societal perspective it plays an important role. 
 
The interval for follow-up in the Markov models is based on an average, since it is difficult to 
make this completely general. Some patients have follow-ups more than weekly, while others 
only have follow-ups on a monthly or even more rarely interval, depending on the patients 
expected outcome of treatment. 
 
The cost and the average amount of patients who receives treatment at the intensive care unit 
is based on expert opinion and is set to be five per cent of the patients. We have not adjusted 
the estimate, as our data set does not provide any information in regards to this. The average 
length of stay at intensive care is also based on a mean, since it was difficult for MD Fløisand 
to provide precise numbers. Some patients stay at the intensive care for a couple of days, 
while others stay for months. The reason for this is that the cause for ending up at intensive 
care can vary. Our average is one week, based on an expert opinion. The cost of intensive 
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care is an estimate by the expert, it could be higher, but adopting a higher cost could be 
misleading on the results. Hence, we chose to rely on the expert.  
 
The cost of patients who receives palliative care is based on DRG-cost and expert opinion. 
Most patients have outpatient visits and blood transfusion two to three times per week. We 
have used this average in both Markov model B (no response) and model C (no induction 
treatment). To track the specific costs of palliative care is too comprehensive for this thesis, 
but one could argue that it would have given more precise cost prediction if conducted. The 
costs of patients in palliative care who are admitted to hospital for shorter periods due to 
infections are not included. Elderly patients suffering from AML who receives palliative care 
might be transferred or enrolled to nursing home, and this has not been included in the thesis 
either. Hence, our results in palliative care might underestimate the true cost of palliative care 
in AML patients. 
 
The cost of palliative care could have been included in the decision tree for patients who 
experience an early death. Additionally, we could have included palliative care for patients 
dying in the Markov models. By including palliative care in these states the costs of patients 
would perhaps been adjusted to a higher total palliative care cost in our results.   
 
The costs in this thesis are a combination of direct costs from the Haematology ward, and 
amounts of recourses manually counted by MD Fløisand, which is multiplied with the price 
by us. This can be a weakness of the estimation. To correct for this we used a standard error 
of +/- 20 per cent. We have tried to make as accurate estimates as possible, and included all 
aspects explained to us by MD Fløisand. Since we are not specialists in the field we had to 
completely rely on the doctor and literature to know what to include. This makes is difficult 
for us to validate the costs.  
 
The cost of transplantation is based on an article written in 2001 (Mishra et al., 2002) and to 
adjust the costs we have used consumer price index calculator to adjust the costs in in 2014 
NOK, which is the period all other costs are tracked from. This can lead to some 
misinterpretations, and one can discuss whether we should have collected the costs associated 
with transplantation specifically for this study. Due to the short time period of conducting our 
study we had to make some appraisals, and we assume that the finding by Mishra et al. 
(2002) is representative.  
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We have used costs from 2014 for the entire model, and to adjust the findings from Mishra et 
al. (2002) we used an American consumer price index calculator (Bureau of Labor Statistics, 
2015), since the cost is denoted in US Dollars. To convert the cost given in British Pounds 
from Wang et al. (2014) we used an inflation calculator from the Bank of England (2015). 
After adjusting respectively Dollars and Pounds to current costs, we converted the values into 
NOK by using a currency converter (Currency Converter, 2015). Lastly, we used an index 
regulator from Statistics Norway (2015) to adjust the costs from 2015 NOK to 2014 NOK, 
since the currency converter was unable to convert the currencies to 2014 NOK. The 
adjustment of the costs might lead to certain skewness, but this should be taken into account 
by the standard error of 20 per cent and the gamma distribution in the uncertainty analysis. 
 
Increased amounts of research on AML treatment is focused on molecular genetic testing and 
the usefulness of this. When being able to track the different genes that affect the outcome of 
treatment the pathways may be more individualised and one can avoid treating patients with a 
poor prognosis. For some patients, palliative care might be a better option instead of going 
through heavy chemotherapies that will not have any positive effect. Similar, one can offer 
transplantation treatment only to patients who will benefit from it. This would also impact the 
cost. 
 
Validation 
Four types of validation are used in our study. It might be a critique that the external 
validation does not completely correspond to our data, but this is probably because the 
Cancer Registry has data from the entire country, while our study only looks at patients from 
OUS. Further, the curves in Figure 29 from the Cancer registry imply that survival is 
increasing. Additionally the cross-validation is not completely fulfilled. This might be 
reasoned by different age composition between our study and the UK. 
 
In the external validation we combined four different curves in one figure. We used a plot 
digitizer application (Plot Digitizer) in order to extract the plot values for implementation of 
the Weibull curve from Stata into Excel. It might lead to some misinterpretation in the 
comparison between the Cancer registry and our model.  
 
Face validation, internal validation and transparency appear to be accomplished.  
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Other issues in the model 
QALY is not included in the study because these data is not collected. Consequently, it is not 
possible to make any economic evaluation based on cost and utility. This can be considered a 
weakness of the study. If QALY was included, this could have led to a reduction in effect of 
certain health states, as QALYs are assigned to account for patient utility (Drummond et al., 
2005).   
 
A study conducted on experienced QOL (quality of life) of AML patients found that most 
patients experience distress and that this can disrupt daily activities and hence affect the QOL 
(Bryant, Walton, Shaw-Kokot, Mayer, & Reeve, 2015). Further, the study by Bryant et al. 
(2015) found that young patients have less dysfunction. All surviving patients have a fairly 
stable physical function and this increase over time. Additionally Bryant et al. (2015) reports 
that 71 per cent of the survivors returned to full-time employment. This study is conducted in 
USA, so it is not definite that this is completely transferable to Norway due to other social 
welfare systems among many factors. QALY seeks to reflect the effect of the intervention on 
a individuals length and quality of life (Briggs et al., 2006). Based on this it can be argued 
that one should have included QALY in the analysis to give a more complete picture of the 
treatment and effect, rather than just considering the survival and cost of the patients.  
 
In the visualisation of the model (Figure 8), in the Markov model D (transplantation), we 
included a state called “remission” following relapse. This state is coloured in grey due to the 
fact that no individuals in our data set reached this. We still chose to include the possibility, 
because technically patients may achieve this. It can be considered a weakness that we were 
unable to track the transition probability of moving to this remission state, and this would 
perhaps be solved if we included more patients in the cohort. 
 
8.4 Findings of similar studies 
The study by Wang et al. (2014) which investigated the survival and treatments costs in the 
UK, found that the life expectancy for this patient group varied from 3.03 months to 34.74 
months. The medical cost was found to range between £ 8 170 and £ 81 636. This is 
approximately equal to NOK 94 386 and NOK 943 117 (unadjusted for inflation). The life 
expectancy depended on the respective treatments, and reflects the heterogeneity in AML 
patients. The cohort involved 352 patients aged 18 and older. Since this study has been used 
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as foundation of our study, some aspects of our findings is appropriate to compare with Wang 
et al. (2014).  
 
In a study by Tangen et al. (2008) the four-year survival of AML patients was found to be 43 
per cent. The study differentiated between the different risks groups, and the results show that 
patients with low-risk AML had a much greater survival than the high-risk groups. The study 
included patients from all the university hospitals in Norway and the cohort consisted of 253 
patients aged between 15 and 61 years. This study does not look at the costs, rather only the 
survival of the different treatments according to risk groups. This make comparisons between 
our study and Tangen et al. (2008) unfeasible.  
 
It does not seem to be as much research on AML with analysis of survival and costs. 
However, it appears that there is a general agreement that the survival of AML patients is 
poor.  
 
8.5 Future research 
We have not included the variable that includes FLT3 (molecular examination) and this 
means that in a future evaluation study this could be implemented and new calculations can 
be made based on this. Additionally, QALYs have not been included and could also be done 
in a future research. If one wanted a more complete picture it could also be interesting to 
investigate the cost of sick leave due to the disease as well as how many who goes back to 
full-time employment. Lastly, if interested, one should include more patients by collecting 
data from all of the Norwegian hospitals that provides AML treatment.  
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9 Conclusion 
 
AML life expectancy and costs vary according to the age of patients and clinical pathway. In 
the probabilistic sensitivity analysis, the total five-year expected cost and life expectancy was 
NOK 1 401 521 and 37.61 months.  
 
When investigating the Markov models individually the highest cost of NOK 999 995 
occurred in A2 (elderly patients responding to treatment), while the lowest cost of NOK 574 
975 occurred for patients who had no response to treatment. Life expectancy was highest in 
model A1 (young patients responding to treatment) and shortest for patients who did not 
respond to induction treatment, with a mean of 47.27 months and 6.15 months, respectively.  
 
Our study is to some extent comparable to the UK. The study shows a higher life expectancy 
with an overall higher total costs relative to the UK. It is important to notice that the study by 
Wang et al. (2014) model an older population than our study. This may lead to better survival 
at generally higher costs in our study compared to the UK study.  
 
More effort should be put in analysing cost and survival of AML patients in order to adopt a 
societal perspective and by including more patients from other hospitals.  
 
This AML model may be used to evaluate treatments and enable policy makers to initiate 
informed decisions. Our model constructed for AML treatment has to be further developed if 
applied in the future due to the constant improvement in treatment and procedures.  
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Appendix A: Screen print Markov C Palliative (Excel) 
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Appendix B: Screen print Markov D Transplant (Excel)
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Appendix C: Screen print Markov A1 Young (Excel) 
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Appendix D: Control cells all Markov models (Excel) 
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Appendix E: Time variables and description of calculation (Excel) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  109 
We started out by looking at how many experience a failure in first remission, during the 
observed period. To do this, we had to define two new variables in Excel; one that specified 
failure and non-failure (1 and 0), and one variable were “time in first remission” was 
calculated. To establish the variable “time in first remission” we subtracted the first occurring 
failure (relapse, transplantation or death) with time in remission, and subtracted this by 1 (to 
“reset” the variables to account for the aging of the patients, since the first patient 
experiencing remission was in month one). This means that if an individual experienced 
relapse in month eight, and the first remission occurred in month 2, that individual had been 
in first remission in 5 months.  
No observed failure indicates that the individual was given 60 (months) of time in remission, 
since this individual would then still be alive and should be included in the analysis. 
Individuals observed in one of the failure states, was coded as 1, else why coded as 0. 
Whenever an individual was more than 60 months in remission this was coded as 0, due to 
the five-year observational period, even though it could have a failure after 60 months. The 
cut-off point for the survival analysis was December 2014. The four individuals diagnosed in 
2015 were left out, since they had not experienced a failure or been in remission long enough. 
Hence the cut was in December 2014. Individuals who did not have any failure, but had not 
survived for 5 years will be censored in Stata.  
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Appendix F: Medication costs and calculation 
The Table below illustrates the input list of medications given to patients at the Haematology 
ward. These numbers was used to calculate the mean cost per patient. Quantity indicates the 
amount of ampules, tablets and bottles in the respective packages of medications. Total 
purchase is the total amount of packages bought at the Haematology ward. All prices shown 
in 2015 NOK, but are adjusted in the calculations. 
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The OUS list of medications we received included prices of medicaments given in cost of 
milligrams (mg) per millilitre (ml). In order to calculate the price of the different dosages 
given, we had to recalculate the different mg per ml into the price per mg. For example, 
Afipran is an infusion that comes in 5 mg/ml. This means that for every ml of Afipran there is 
5 mg of the substance. We used the cost per ml, divided it by the amount of mg, and found 
the price per mg by conducting the following steps: First, we found the price per package 
divided by the volume in each package, second, the cost found in the first step divided by the 
mg per unit. In the example of Afipran this will be 61,10 (price per package) / 20 (the volume 
in each package), and then 3,06 (the price per volume) / 5 (amount of mg per ml). This gives 
a price of NOK 0,611 per mg. Further; we know that the dosage of Afipran is 10 * 4 mg per 
day for 7 days. When multiplying the cost of Afipran with the dosage this gives a cost of 
NOK (10*4*7)*0,611 which is NOK 171,08. For some of the medications we had two or 
three different prices listed, and this was also the case for Afipran. In order to take this into 
account we did the same steps as described above for all of the different versions of the 
substance. The second cost we calculated for Afipran was the version of the medication that 
contained a different combination of ampoules in the packages. The cost for this version is 
NOK 0,3619 per mg. To find out which price accordingly to use, we incorporated the number 
of packages sold of each version and calculated the distribution in per cent. Next we 
discovered that they had bought 87 % of theversion of a mg price of 0,3619 and 13 % of the 
version with a mg price of 0,611. We used this fraction and multiplied it with the respective 
prices. A new price was then calculated based on the estimated distribution and the cost per 
mg were then 0,394. When multiplying this with dosage (10*4*7) we get a new cost of 
Afipran of NOK 110,32. These steps were done for all medications that were used (different 
brands) in order to get the correct price according to the billed prices at the Haematology 
ward.  
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Appendix G: SPSS Variables 
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Appendix H: Hazard function sheet (Excel) 
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Appendix I: Hazard function sheet (Excel) 
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Appendix J: HOVON (treatment strategies) 
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Appendix K: Costs at OUS Haematology ward 
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Appendix L: Decision tree (Excel) 
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Appendix M: Wages at Haematology ward  
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Appendix N: Stata do-file 
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